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Swelling-activated Cl− current (ICl,swell) is an outwardly-rectifying current that plays an important 
role in cardiac electrical activity, cellular volume regulation, apoptosis, and acts as a potential 
effector of mechanoelectrical feedback. Persistent activation of ICl,swell has been observed in 
models of cardiovascular disease. We previously suggested sphingosine-1-phosphate (S1P) 
activates volume-sensitive Cl- current (ICl,swell) by ROS-dependent signaling. S1P and its analog, 
FTY720 (fingolimod), primarily act via G-protein coupled receptors (S1PR; S1PR1-3 in heart), 
but several intracellular S1P ligands are known. We investigated how these agents regulate 
ICl,swell. ICl,swell was elicited by bath S1P (500 nM), FTY720 (S1PR1,3 agonist; 10 μM), and 
SEW2871 (S1PR1 agonist; 10 μM) and was fully inhibited by DCPIB, a specific blocker. These 
data suggested role of S1PR in activation of ICl,swell. Surprisingly, neither CAY10444 (S1PR3 
antagonist; 10 μM) nor VPC23019 (S1PR1,3 antagonist; 13 μM) blocked FTY720-induced 
ICl,swell. Also, gallein a pan Gβγ inhibitor, failed to block the S1P-induced current. Moreover, 
100 nM FTY720 applied via the pipette evoked a larger, faster activating current than 10 μM 
bath FTY720. Similarly, 500 nM S1P gave larger, faster activating ICl,swell when added to the 
pipette than when added in the bath. In contrast to FTY720, bath S1P-induced ICl,swell was 
blocked by CAY10444, but a 3-fold higher concentration failed to eliminate the response to 
pipette S1P, and VPC23019 failed to suppress bath and pipette S1P-induced currents. Taken 
together, inconsistencies in the responses to S1PR agents and the greater sensitivity to pipette 
than bath S1P and FTY720 support the notion that intracellular ligands rather than sarcolemmal 
S1PR activated ICl,swell. Next we tested if S1P and FTY720, like osmotic swelling, require both 
NADPH oxidase and mitochondrial ROS production to evoke ICl,swell. S1P- and FTY720-
induced ICl,swell were blocked by rotenone but were insensitive to gp91ds-tat, suggesting only 
 
 
xvii 
 
mitochondrial ROS production was needed. One possibility is that S1P and FTY720 elicit 
ICl,swell by binding to mitochondrial prohibitin-2, an S1P ligand whose knockdown augments 
mitochondrial ROS productions. These data suggest ICl,swell may be activated by S1P 
accumulation in ischemia-reperfusion and CHF. Understanding S1P-signaling that elicits ICl,swell 
may provide insight into electrophysiological mechanisms of cardiac pathology and help identify 
novel targets for therapy. 
 
 
 
1 
 
Chapter 1 Background 
 
 
 
 
1.1. Introduction of ICl,swell  
 The swelling-activated chloride current (ICl,swell), also referred to as the volume-sensitive 
chloride current (ICl,vol), volume-activated channel (VAC), or volume-sensitive organic osmolyte 
anion channel (VSOAC), is present in virtually all cell types and elicits an outwardly rectifying 
chloride current. ICl,swell can be differentiated from other chloride channels based on the several 
biophysical and pharmacological properties. The current is outwardly rectifying under 
physiological or symmetrical chloride gradient and partially inactivates at positive potentials. 
Also current is time-independent over the physiologic voltage range and is attenuated by osmotic 
shrinkage. The permeability sequence is I_≥NO>Br_>Cl_>Asp (Hume et al., 2000;Baumgarten 
& Clemo, 2003). Although the molecular identity is not yet determined, extensive 
pharmacological studies have been reported in various tissues. ICl,swell is inhibited by class of 
molecules including Cl-channel blockers, the antioestrogen such as tamoxifen, clomiphen, and 
nafoxidine at micro molar concentrations; antimalarials such as mefloquine, gossypol, 
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arachidonic acid, chromones, quinine, and quinidine, other compounds such as 9-Anthracene 
carboxylic acid (9-AC), nordihydroguaiaretic acid (NDGA), a dual inhibitor of cyclooxygenase 
and lipoxygenase, 1,9-dideoxyforskolin, the oxalon dye diBA-5-C4, niflumic acid, mibefradil, a 
T-type Ca2+ channel blocker, glibenclamide, a KATP and CFTR inhibitor, and by NPPB. It is also 
inhibited in voltage dependent manner at positive potentials by molecules such as calixarenes, 
DIDS, SITS (Nilius & Droogmans, 2003). The most selective blocker of ICl,swell identified so far 
is the indanone compound DCPIB, which works at micromolar concentrations and was 
characterized in detail for cardiac ICl,swell (Decher et al., 2001). Recent studies suggest, however, 
that DCPIB also blocks GIRK channels, although with lower potency (W Deng, R Mahajan, CM 
Baumgarten, and DE Logothetis, unpublished observation. 2011). 
1.1.1. Function of ICl,swell  
 As the name implicates ICl,swell is stimulated by an increase in cell volume or osmotic 
swelling, as well as other stimuli. Swelling-activated chloride channels are ubiquitously present 
in mammals, in all cell types (Nilius et al., 1994;Okada, 1997) including cardiac cells (Tseng, 
1992;Sorota, 1992) and are involved in cell volume regulation and many other functions. The 
molecular identity remains elusive. However various groups are actively involved in 
investigating and understanding its role in cell volume regulation, regulatory volume decrease 
(RVD) during apoptosis (Okada & Maeno, 2001;Shimizu et al., 2004), cell proliferation (Chen et 
al., 2007), and cell cycle progression and migration (Mao et al., 2009). ICl,swell is implicated in 
fluid and electrolyte transport; for instance in ciliary epithelium cells, regulates secretion of 
aqueous humor (Jacob, 1997). Cell proliferation in many cell types such as T lymphocytes, 
microglia, astrocytoma cells, endothelial cells, and liver cells is regulated by ICl,swell (Nilius & 
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Droogmans, 2003). ICl,swell is thought to be involved in cell cycle progression as well (Stutzin & 
Hoffmann, 2006). Additionally ICl,swell is important in apoptotic volume decrease (AVD), 
evidenced by decrease in AVD by blocking the channel (Okada & Maeno, 2001). AVD is known 
to be an upstream mediator of the events during apoptosis (Maeno et al., 2000). Since AVD is 
regulated by chloride channel, therefore interpretation of ICl,swell as a regulator of apoptosis seems 
reasonable. Depletion in cholesterol content activates ICl,swell, under isoosmotic conditions, 
however the relationship between ICl,swell and membrane cholesterol content remains unexplored 
(Stutzin & Hoffmann, 2006). Recent work from our lab suggests that a high cholesterol diet 
activated ICl,swell, in LDL receptor null control macrophages by increasing mitochondrial ROS 
production, and that depleting the cholesterol ester by macrophage-specific transgenic over 
expression of human cholesterol ester hydrolase inhibited ICl,swell (Deng et al., 2011). 
 In cardiac physiology the role of chloride channel is still unclear, but it is thought to be 
important in cell volume regulation (Hoffmann & Dunham, 1995), a modulator of electrical 
activity and protects against ischemic reperfusion injury (Mulvaney et al., 2000). Furthermore 
the channel plays diverse role such as altering resting membrane potential and the duration of 
action potential, hence acting as an important modulator in physiological and patho-
physiological condition (Hume et al., 2000). ICl,swell is known to regulate cardiac electrical 
activity, cell volume, apoptosis, cell proliferation and probably serves a role in ischemic 
preconditioning (Baumgarten et al., 2005;Duan et al., 2005;Hume et al., 2000). ICl,swell is 
activated by β1 integrin stretch, hydrostatic inflation, also it is found to be activated under 
isoosmotic environment in various models of cardiac diseases. The molecular identity of this 
channel remains controversial, as well as the volume sensing mechanism responsible for 
activation of channel. 
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1.2. Regulation of ICl,swell  
 Over the past few years the signaling molecules regulating the channel have been actively 
studied. Reactive oxygen species (ROS) seem to be an effective modulator of ICl,swell in cardio-
myocytes (Browe & Baumgarten, 2006;Browe & Baumgarten, 2004;Ren et al., 2008) and other 
cells (Haskew-Layton et al., 2005;Shimizu et al., 2004;Varela et al., 2004).  
1.2.1. Indirect evidence of regulation of ICl,swell by ROS in heart and other tissue 
 d’Anglemont de Tassigny et al. (2004) looked at the role of a Cl- current thought to be 
ICl,swell and AVD in doxorubicin-induced apoptotic cell death in adult rabbit ventricular 
cardiomyocytes. The observations included activation of an outwardly rectifying Cl- current 
upon exposure to doxorubicin and C2-ceramide. Also inhibition of chloride channel led to 
attenuation of programmed cell death by decreasing caspase activity and annexin V labeling (de 
Tassigny et al., 2008). However, identification of the current as ICl,swell was lacking. The anion 
channel inhibitors utilized were not selective for ICl,swell, the doxorubicin- and C2-ceramide-
induced currents were not shown to be volume-sensitive, and outward rectification in 
symmetrical Cl- was not verified. Doxorubicin is known as a proapototic agent, which induce 
oxidative stress in myocytes, but the role of ROS in current activation was not demonstrated. 
Current activation was blocked by inhibitors of PI3 kinase/AKT (de Tassigny et al., 2008), and 
we demonstrated activation of PI3 kinase by EGFR upregulated ICl,swell via ROS in response to 
osmotic swelling and mechanical stretch (Ren et al., 2008;Browe & Baumgarten, 2006). 
Xiaoming Wang et al. showed that activation of ICl,swell during the reperfusion period led to 
induction of apoptosis in neonatal mouse cardiomyocyte during ischemia-reperfusion. Elicitation 
of current was shown to be modulated by ROS. They demonstrated ROS production during 
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period of reperfusion, also application of non selective inhibitors of channel during the period of 
reperfusion but not ischemia reduced cell death by apoptosis. In addition ROS scavengers 
prevented apoptosis by reduction of caspase activation (Wang et al., 2005). Additionally they 
showed apoptosis and Cl- channel blockers act independent of the Cl-/HCO3 exchanger. Though 
direct evidence of ROS modulating chloride channel activation was not shown, it is clear from 
previous studies in endothelium cells that ICl,swell is involved in apoptosis and regulated by ROS 
(Shimizu et al., 2004). 
 Another group reported the importance of volume regulation via ICl,swell in ischemic 
preconditioning (IP). Ischemic preconditioning is known to activate ROS production. Though 
many controversies were reported, Baines et al. demonstrated production of ROS during 
ischemic preconditioning and their role in cardioprotection (Baines et al., 1997). Moreover in 
another study blockade of chloride channel during IP and pharmacological preconditioning 
(PPC) failed to offer cardioprotection. The players such as angiotensin II, AT receptors, 
adenosine, PKC which are involved in PPC are known to modulate chloride channel. Batthish et 
al. showed that chloride channels play an important physiological role in the cardioprotection of 
IPC and PPC acting downstream of PKC (Batthish et al., 2002;Diaz et al., 2001). From the 
above studies indirect involvement of ROS can be inferred. More precise experiments are needed 
to show involvement of ROS as a modualtor of ICl,swell. Many of these study fail to use specific 
inhibitor of ICl,swell, and therefore, evidence of the role of this channel may be questioned. 
Additionally linking of various upstream mediators of ROS production and how it modulates 
ICl,swell still poses a challenge. Also the source of ROS production upon stimulation by various 
upstream mediators is also elusive. 
1.2.2 Regulation of ICl,swell by ROS in heart 
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 Recently, reactive oxygen species (ROS) were identified as a downstream effector, and 
exogenous H2O2 elicits ICl,swell in cardiomyocytes (Ren et al., 2008;Browe & Baumgarten, 
2006;Browe & Baumgarten, 2004) and other cells (Haskew-Layton et al., 2005;Shimizu et al., 
2004;Varela et al., 2004). Baumgarten and coworkers, demonstrated β1 integrin stretch and 
osmotic swelling, activating volume sensitive chloride current in cardiac myocytes. Upstream 
signaling molecules include Src family kinases (Browe & Baumgarten, 2003;Du et al., 
2004;Walsh & Zhang, 2005), protein tyrosine kinase (Sorota, 1995), angiotensin II (Ang II) 
(Browe & Baumgarten, 2004;Ren et al., 2008), epidermal growth factor receptor (EGFR) kinase 
(Du et al., 2004), and phosphoinositide 3-kinase (PI-3K) (Browe & Baumgarten, 2006;Ren et al., 
2008). Protein kinase C (PKC) also is implicated, although its role is controversial because it 
appears to inhibit (Duan et al., 1999) or activate ICl,swell (Gong et al., 2004;Duan et al., 1999). 
Moreover ET-1-induced ICl,swell was abrogated by selective blockade of ETA receptor, EGFR 
kinase and PI-3K, suggesting that ET-1 activates (Deng et al., 2010a). ICl,swell via a signaling 
cascade involving ETA receptor, EGFR kinase and PI-3K. PI-3K is downstream from EGFR 
kinase because inhibition of PI-3K suppressed EGF-induced ICl,swell. All these signaling cascade 
indicated H2O2 as the most downstream modulator for ICl,swell. Scavenging H2O2 with catalase 
reverses the β-integrin stretch-induced activation of ICl,swell (Browe & Baumgarten, 2005). 
Moreover, the SOD mimetic MnTBAP that speeds conversion of superoxide (O2−•) to H2O2 
augments ACh-induced ICl,swell (Browe & Baumgarten, 2007). ICl,swell also is activated by 
exogenous H2O2 with an EC50 of ~8 μM (Browe & Baumgarten, 2004;Ren et al., 2008), and the 
site of action of H2O2 appears to be downstream from the volume-sensing mechanism because 
H2O2-induced current is insensitive to hyperosmotic shrinkage (Ren et al., 2008). Potential 
sources for ROS in cardiomyocytes include NADPH oxidase (NOX) and the mitochondrial 
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electron transport chain (ETC). Both have been implicated in activation of ICl,swell (Browe & 
Baumgarten, 2004;Browe & Baumgarten, 2007;Ren et al., 2008;Deng & Baumgarten, 2009). 
However H1V protease inhibitor ritonavir and lopinavir activated ICl,swell via mitochondrial ROS 
production that was independent of NADPH oxidase (Deng et al., 2010b). Furthermore SMase-
induced ICl,swell, inhibitor of NADPH oxidase partially reduced the S1P-induced Cl− current and 
inhibitor of mitochondrial ROS completely abolished SMase induced current (Raucci & 
Baumgarten, 2009). Although strong evidence is provided for the signaling pathway involved in 
modulation of the channel, the studies are based on use of pharmacological inhibitors. Though 
these have been implicated as specific inhibitors, their non-specific effect cannot be ruled out. 
There also may be additional players in the cascade which are not yet evident. Hence these 
studies can by no means present a complete understanding of the signaling molecules involved in 
activation of ICl,swell. 
1.3. Importance of sphingolipid signaling in modulation of ICl,swell 
 Many of the signaling cascades that activate ICl,swell overlap with those involved in 
sphingolipid signaling (Hannun & Obeid, 2008;Levade et al., 2001;Spiegel & Milstien, 2002) 
raising the possibility that certain sphingolipids might regulate ICl,swell. Sphingolipids are 
important bioactive lipid metabolites which play an important role in cell growth, apoptosis, 
motility, vasculogenesis, and immune function. Sphingolipid metabolism is altered in several 
cardiac diseases resulting in their accumulation (Chatterjee et al., 2006;Levade et al., 2001). 
Extensive studies in multiple tissues have focused on the sphingolipid metabolites sphingosine 1-
phosphate (S1P), sphingosine, and ceramide. The maintenance of a balance between ceramide 
and S1P levels is important in determining the fate of cells (Van Brocklyn & Williams, 2012). 
Enzymes such as sphingomyelinase and sphingosine kinase (SphK) play a key role in the 
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production of these metabolites. Sphingosine kinase (SphK)/S1P pathway acts as regulator of 
various cellular signaling cascades. Recently SphK/S1P was found to have a role in cardiac 
physiology and pathology including ischemic/reperfusion injury. Alterations in sphingolipid 
metabolism are implicated in cardiovascular diseases, including congestive heart failure, 
atherosclerosis, and ischemia/reperfusion injury (Levade et al., 2001;Chatterjee et al., 2006). 
S1P is known to act as a ligand for G-protein coupled S1P receptors to initiate signaling pathway 
regulating many cellular functions. Moreover S1P regulates cardiac ion channel activity. 
Recently our laboratory showed that exogenous and endogenous ceramide elicited ICl,swell in 
ventricular myocytes via ROS. Preliminary data suggests, however, that the ceramide metabolite 
S1P rather than ceramide itself was responsible for activating ICl,swell. Because of the well-
established role of G protein-coupled S1P receptors in transducing S1P signaling (Means & 
Brown, 2009), we hypothesized that SphK/S1P pathway and the three cardiac G protein coupled 
S1P receptors (S1PR1-3) were responsible for triggering activation of ICl,swell under isosmotic 
conditions  by ROS production by either NADPH oxidase, mitochondria or both. More recently, 
intracellular S1P binding sites also have been reported in cardiac and other cells (Hait et al., 
2013;Maceyka et al., 2012). Among these is prohibitin 2 (PHB2), a mitochondrial inner 
membrane protein that controls the assembly and function of cytochrome oxidase. This leads to 
an alternative hypothesis that S1P elicits ICl,swell via its binding to intracellular target(s) rather 
than plasmalemmal S1P receptors. 
1.4. Sphingolipds 
1.4.1. Role of Sphingolipds 
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 Until recently sphingolipids were considered merely as membrane structural components 
without further function. In the past two decades sphingolipids have been identified as important 
bioactive lipids that are involved in various functions ranging from pleiotropic effects on protein 
kinases, regulating the actin cytoskeleton, endocytosis, the cell cycle and apoptosis (Smith et al., 
2000). They are involved in forming specialized structures, mediate cell-cell and cell-substratum 
interactions, modulate the behavior of cellular proteins and receptors, and participate in signal 
transduction and the activation of downstream cascades. Sphingolipids are usually classified into 
two separate groups: sphingophospholipids, which include sphingomyelin, ceramide, 
sphingosine and the phosphorylated forms of these lipids, and glycosphingolipids, which include 
gangliosides. Amongst sphingolipid metabolites the most prominent are sphingosine 1-Phosphate 
(S1P), sphingosine, and ceramide. Ceramide mediates many cell-stress responses, including the 
regulation of apoptosis (Obeid et al., 1993) and cell senescence (Venable et al., 1995) , whereas 
S1P has crucial roles in cell survival, cell migration and inflammation (Spiegel & Milstien, 
2002). The maintenance of a balance between ceramide and S1P levels seems important in 
determining the fate of cells (Van Brocklyn & Williams, 2012).  
1.4.2. Biosynthesis and Metabolism  
 Sphingolipids are ubiquitous components of the lipid bilayer in all eukaryotic cells. 
Ceramide, which is a backbone for most of sphingolipids, is a precursor for formation of S1P, 
and key elements of the pathway regulating S1P production are illustrated in Figure 1. Ceramide 
can be synthesized by either a de novo pathway or a degradative pathway through the hydrolysis 
of complex lipids, especially sphingomyelin (SM). De novo synthesis of sphingolipids occurs at 
the cytosolic face of the endoplasmic reticulum (ER). The initiating reaction is the condensation 
of serine and palmitoyl-CoA catalyzed by serine palmitoyltransferase to form 3-ketosphinganine,  
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Figure 1: Schematic of S1P metabolism pathway (Bartke & Hannun, 2009). Key 
abbreviations include sphingomyelinase (SMase), sphingosine kinase (SK). 
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which is rapidly reduced to dihydrosphingosine and then N-acylated by ceramide synthase to 
form dihydroceramide. Finally, a trans double bond at C4–C5 is introduced by dihydroceramide 
desaturase, producing ceramide (Bartke & Hannun, 2009). Ceramide is then transported from the 
ER to Golgi where head groups are added forming sphingolipids. Later, ceramide is acted upon 
by ceremidase to yield sphingosine, the most common base for other sphingolipids. Finally, 
SphK catalyzes ATP-dependent phosphorylation of sphingosine to form S1P. S1P is converted 
back to sphingosine, which can be recycled, by sphingosine phosphatase. Alternatively, S1P can 
be irreversibly broken down by S1P lyases to hexadecanal and phosphoethanolamine which then 
can be incorporated into lipids (Spiegel & Milstien, 2003).  
 Although de novo synthesis is an important source of sphingosine in cells, much of the 
sphingosine present under physiological and several pathological conditions is generated by the 
catabolism of sphingomyelin and other sphingolipids, a process termed as the degradative 
pathway (Kitatani et al., 2008) . This pathway involves release of ceramide from sphingomyelin 
by sphingomyelinase, and in turn, ceramide is acted upon by ceramidases to generate 
sphingosine. Additionally, ceramide is produced through a salvage pathway that begins within 
acidic cellular compartments including late endosomes and lysosomes (Kitatani et al., 2008). 
Importantly sphingosine and dihydrosphingosine (sphinganine) are not produced by either the de 
novo pathway and or catabolism (Strub et al., 2010).  
 Sphingosine-1 phosphate (S1P) is produced by the action of sphingosine kinases. There 
are two primary isotypes of sphingosine kinase, denoted as SphK1 and SphK2, that produce S1P 
in the cytosol, and SphK are stimulated by various growth factors and other molecules. 
Interestingly, the best studied biological actions of S1P via G protein-coupled S1PR requires 
inside-out signaling (Takabe et al., 2008). Cytosolic S1P is transported out of the cell via ABC 
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transporters. Once in the extracellular space, S1P acts as a potent S1PR ligand and activates 
downstream intracellular signaling cascades in autocrine/paracrine manner (Takabe et al., 
2008;Alvarez et al., 2007;Spiegel & Milstien, 2000). In cardiovascular system three G protein-
coupled S1P receptors, S1P1-3, are expressed (Means & Brown, 2009). S1P1 receptor exclusively 
couples with Gi, whereas S1P2 S1P3 couple to Gi, Gq, and G12/13. 
1.4.3. Sphingosine Kinase (SphK)  
 SphK are lipid kinases that catalyze production of S1P from sphingosine by ATP-
dependent phosphorylation. Figure 2 shows the conversion of sphingosine to S1P and list the 
various downstream targets and potential functions of both sphingosine and S1P (Spiegel & 
Milstien, 2002). SphK is a key regulator that determines cell fate. SphK belong to a conserved 
lipid kinase family containing 5 conserved domains (Kohama et al., 1998). Two mammalian 
isoforms are known: SphK1 and SphK2. While both isoforms produce S1P, they exhibit different 
catalytic properties, subcellular locations, tissue distribution, and temporal expression patterns 
during development, suggesting unique and specific functions. For example, SphK1 and SphK2 
have opposing roles in regulation of ceramide biosynthesis (Maceyka et al., 2005). The genes 
encoding the isoform are located on different chromosomes. SphK1 has a broad tissue 
distribution with high levels in brain, heart, lungs and spleen. SphK1 displays specificity for the 
natural trans-isomer of D-erythrosphingosine. The second isoform, SphK2, shares five conserved 
domains with SphK1 (about 80% similarity and 50% identity), but it has an additional 200 amino 
acids. SphK2 phosphorylates wider range of sphingolipid base substrate (Hait et al., 
2006;Karliner, 2009b).  
 SphK is stimulated by various external stimuli. Activators include agonist of growth 
factor receptors, such as PDGF, VEGF, NGF, and EGF, ligands for GPCRs, TGFβ, the  
13 
 
 
 
  
 
 
Figure 2: Conversion of D-erythro-sphingosine to S1P by SPHKs, using 
ATP as the phosphate donor. Various downstream targets and potential 
functions of both sphingosine and S1P are mentioned (Spiegel & 
Milstien, 2002). 
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proinflammatory cytokine TNF-alpha, cross-linking of IgE and IgG receptor, interleukins, 
estrogen, and activators of PKCε. A variety of other interacting adaptor protein specifically 
stimulates SphK1 activation. The growth factors are responsible for translocation of SphK1 to 
the plasma membrane (Spiegel & Milstien, 2003). Thus, S1P produced by translocation of 
SphK1 to the plasma membrane has been implicated in transactivation of cell surface S1P 
receptors (Maceyka et al., 2005). In most cases, the importance of SphK1 activation and 
concomitant production of S1P in the regulation of many biologically responses was only 
indirectly inferred by the ability of pan SphK inhibitors to block agonist-induced effects (Hait et 
al., 2006;Spiegel & Milstien, 2002). In contrast to SphK1, SphK2 is mainly present in 
intracellular compartments, including the nucleus and mitochondria. Nuclear SphK2 regulates 
gene transcription at least in part by producing S1P, which acts as an endogenous inhibitor of 
histone deacetylases (Hait et al., 2009). In mitochondria the action(s) of SphK2 are required for 
correct assembly of the cytochrome oxidase complex. However, the exact ligand for the 
mitochondrial targeting signal is not known (Strub et al., 2011).  
 Relatively little is known about the signaling pathways that regulate SphK2 activity. 
Studies indicate that pro-survival protein Bcl-xL activates (Liu et al., 2003) SphK2. There is 
strong evidence that disordered or altered cell volume regulation is associated with apoptosis 
(Maeno et al., 2000;Okada & Maeno, 2001). ICl,swell is known to regulate the apoptotic cell 
volume (Okada et al., 2006). There is also a link between the apoptotic resistance, offered by 
survival protein Bcl-2 and the strengthening of RVD capability by upregulation of ICl,swell.(Shen 
et al., 2002;Lemonnier et al., 2004). Thus S1P produced by the action of SphK2 due to BCl-xl 
activation could be responsible to modulate the activity of ICl,swell. Similar to SphK1, SphK2 is 
upregulated by the Erk1/2 pathway. SphK 2 and SphK1 have opposing functions in ceramide 
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signaling (Spiegel & Milstien, 2003). The differences between the pro-survival and anti-survival 
effects of SphK are related to the distinct sub-cellular localization and spatially restricted 
production of S1P (Karliner, 2009b). But these differences are not yet demonstrated in cardiac 
cells or in vivo in any organs. 
1.5. Sphingosine-1 Phosphate: Important Signaling Biolipid 
 Sphingolipids have been extensively studied for the past two decades. The pathways in 
which sphingolipids work are enigmatic, however, various signaling cascades have been 
identified. The unprecedented complexities in sphingolipid biochemical interconnections enable 
cells to execute cellular responses by regulating sphingolipid inter-conversions. Therefore, it is 
important to determine which sphingolipid is responsible for orchestrating a particular signaling 
pathway. Amongst several sphingolipids, the S1P/ceramide rheostat plays a critical role in 
determining the fate of the cell (Van Brocklyn & Williams, 2012). This notion is supported by 
the fact that S1P and ceramide control the cell-cycle process (Spiegel & Milstien, 2002) and 
apoptotic (Obeid et al., 1993) pathway, respectively. Thus, S1P and ceramide have antagonistic 
effect on the cell. However, recently it has been shown that ceramide and S1P can have similar 
effects in certain circumstances. For example, both ceramide and S1P induced ROS generation in 
bovine coronary arteries (Zhang et al., 2003;Keller et al., 2006).  
 After establishing the role of S1P in cell growth (Olivera & Spiegel, 1993;Zhang et al., 
1991), studies have aimed at determining the role of SphK in setting the level of S1P in different 
cellular compartment, the compartment-specific actions of S1P, and more broadly, the signaling 
cascades triggered by plasmalemmal S1P receptors. The primary step in signal transduction is 
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inside-out S1P transport and binding to G-protein coupled S1P receptors (S1PR). However the 
importance and role of potential intracellular S1P binding targets remains unclear.  
1.5.1. Inside-out transport of S1P 
 S1P produced by the SphK can act in a paracrine-autocrine manner and bind 5 S1P 
receptors (S1P1-5) that are expressed in various tissues (Chun et al., 2002;Spiegel & Milstien, 
2000), although only S1P1-3 have been identified in cardiac myocytes (Means & Brown, 2009). 
Because S1P is synthesized in the cytosol and binds to G protein-coupled receptors facing the 
extracellular milieu, this bioactive lipid must be transported from the inside to the outside of cells 
to act. Inside-out transport of S1P and presumably its analog FTY720-P are mediated via several 
ATP-binding cassette (ABC) proteins known as ABC transporters, including ABCA1, ABCB1, 
ABCC1, and ABCG2 (Sato et al., 2007;Nieuwenhuis et al., 2009;Honig et al., 2003;Takabe et 
al., 2010). In mast cells, for example, the ABCC1 transporter is responsible for S1P export 
(Mitra et al., 2006). In astrocyte ABCA1 transports S1P out of the cells (Sato et al., 2007). 
Similarly, S1P secretion from platelets is also mediated by an ABC transporter, ABCA7 
(Kobayashi et al., 2006;Anada et al., 2007), and in breast cancer cells, stimulation with estradiol 
led to S1P release via ABCC1 and ABCG2  transporters (Takabe et al., 2010). However, the 
involvement of ABC transporters in the secretion of S1P in a number of other systems, including 
cardiac myocytes, is yet to be determined, and knock out of selected ABC transporters does not 
fully reproduce the expected phenotype. Recently human Spns2, a putative 12-transmembrane 
domain protein, was shown to transport S1P, dihydro-S1P, and FTY720-P in CHO cells (Hisano 
et al., 2011). Interestingly, Spns2 regulates the migration of myocardial precursors during 
Zebrafish development (Kawahara et al., 2009) by regulating S1P secretion from the 
extraembryonic yolk syncytial layer, and Spns2 mRNA is found in homogenates of human heart 
17 
 
 
 
(Hisano et al., 2011). In addition to its local autocrine/paracrine action, S1P is synthesized 
(Yatomi et al., 1997) and released from platelets in response to thrombin stimulation (Yatomi et 
al., 1995) and erythrocytes (Hanel et al., 1993). S1P levels in the extracellular fluids plasma 
(associated with albumin or lipoproteins (Aoki et al., 2005;Hla, 2005;Murata et al., 2000;Yatomi 
et al., 2000)) and lymph are generally high, with concentrations reported of 200 nM to 3 μM and 
up to 500 nM (Hla, 2005), respectively (Kihara & Igarashi, 2008). In our experiments we use 
500 nM S1P to match closely with the physiological concentration. 
1.5.2. Extracellular targets of S1P signaling  
 As mentioned above, S1P acts as a ligand for the family of five G protein-coupled 
receptors, termed S1PR1-5, formerly called endothelial differentiation gene (EDG) receptors. 
These receptors are differentially expressed across tissues and are coupled to different G proteins 
resulting in diverse signaling by S1P. Amongst the array of responses evoked upon S1P binding 
to the GPC receptors are Ca2+ mobilization, proliferation, cytoskeletal organization and 
migration, adherence- and tight junction assembly, and morphogenesis (Hla, 2004;Lee et al., 
1999). As mentioned previously, to date, five members of the S1PR family have been cloned 
including S1P1 (EDG-1), S1P2 (EDG- 5), S1P3 (EDG-3), S1P4 (EDG-6), and S1P5 (EDG-8) all 
of which bind and are activated specifically by S1P and dihydro-S1P (also known as sphinganine 
1-phosphate) (Chun et al., 2002), whose structure is identical to that of S1P but lacks the 4,5-
trans double bond). S1P thus is able to activate and regulate a diverse array of signal 
transduction pathways in different cell types, depending on the relative abundance of S1PRs and 
associated G proteins, and elicit a wide range of responses (Spiegel & Milstien, 2000;Pyne & 
Pyne, 2000). Localization and G protein coupling of each of the S1P receptors and their 
signaling upon activation will be described in the following sections. 
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1.5.3. S1PR1 
 S1PR1, historically known as EDG1, was the first receptor S1PR identified. It is 
ubiquitously expressed with high levels in brain, lung spleen, cardiovascular system and kidney 
and is coupled to Gi/o. Initially S1PR1 was thought to be an orphan GPCR receptor responsible 
for differentiation of endothelial cells (Brinkmann, 2007). Further studies confirmed S1PR1 
possessed high affinity for S1P (Kd 8.1 nM using radioligand binding assay in HEK293.(Lee et 
al., 1998) and 13.2 nM estimated by [3H]S1P in Chinese hamster ovary cells transfected with 
putative S1P receptor (Kon et al., 1999). Genetic deletion of S1P1 in mice indicates a key role in 
angiogenesis and neurogenesis. The observation that S1PR1 plays a critical role in directed cell 
motility suggests the underlying mechanism by which S1P acts as a regulator of angiogenesis 
(Liu et al., 2000). Additionally, S1PR1 plays a role in the regulation of immune cell trafficking, 
endothelial and epithelial barrier function and integrity (Singleton et al., 2005). Also it has a key 
role in angiogenesis, vascular maturation, increased vascular integrity (Singleton et al., 2005), 
and maintaining vascular tone (Sanna et al., 2004). The maintenance of vascular integrity is 
carried out by downstream activation of Akt and Rac upon S1PR1 activation (Singleton et al., 
2005). Additionally, binding of S1P to S1PR1 can transactivate various growth factor receptor 
tyrosine kinases (RTKs), such as VEGF receptor, EGF receptor, and PDGF receptor (Takabe et 
al., 2008). Forming a complex with VEGFR, it associates with PKC alpha and ERK1/2 (Bergelin 
et al., 2010). The signaling triggered by S1PR is summarized in Fig. 3 (Pyne & Pyne, 2000). 
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Figure 3: Signaling pathways activated by S1P binding to EDG/S1P 
receptors regulating mitogenesis, chemotaxis, diﬀerentiation and 
apoptosis. Diﬀerential coupling to G-proteins and eﬀectors for S1PR1-3may 
be apparent for EDG1, EDG3 and EDG5. Abbreviations : AC, adenylate 
cyclase ; PIP2 , PtdIns(4,5)P2; IP3, Ins(1,4,5)P3 ; DG,diacylglcerol ; AP1, 
activator protein 1 (Pyne & Pyne, 2000). 
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S1PR1 is also involved in immune function of cell by modulating lymphocyte recirculation 
(Strub et al., 2010). This underlies the clinical utility of fingolimod (FTY720; Gilenya), an 
immunosupressor recently approved for the treatment of relapsing forms of multiple sclerosis. 
FTY720 is a sphingosine analog prodrug that is converted to its active form by phosphorylation 
by SphK and induces lymphopenia (Brinkmann et al., 2002;Mandala et al., 2002). 
1.5.4. S1PR2 
 S1PR2 was originally known as EDG5. Like S1PR1, S1PR2 is also widely distributed and 
is prominently expressed in vascular smooth muscle cells (Waeber et al., 2004). It is coupled to 
Gi/o, Gq, and G12/13, thereby imparting a wide range of actions. In contrast to S1PR1, S1PR2 
receptors inhibit migration and proliferation of endothelial and vascular smooth muscle cells, 
probably because of their unique stimulatory effect on a GTPase-activating protein that inhibits 
Rac activity (Waeber et al., 2004). S1PR2 also play an essential role in the proper functioning of 
the auditory and vestibular systems, as S1PR2 knockout mice exhibit deafness (Kono et al., 
2007). This S1P receptor is also required for degranulation of mast cells. Moreover, S1PR2 are 
important for pyramidal neuron development and the regulation of excitability, as their loss 
causes increased excitability and seizures that can be lethal (MacLennan et al., 2001). S1PR2 
activates Rho, PLC, c-Jun, JNK, p38 and inhibits Rac. Additionally, it inhibits tumor 
angiogenesis and growth (Yester et al., 2011). The affinity of S1PR2 for S1P is (Kd 20–27 nM) 
(Ishii et al., 2004).  
1.5.5. S1PR3 
 S1PR3, also known as EDG3, is coupled with Gi/o, Gq, and G12/13. Similar to S1PR1, it has 
a wide range of distribution throughout the body with predominant expression in heart, peri-
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vascular smooth muscle cells, lung, spleen, kidney, intestine, diaphragm, and cartilage. The 
signaling pathway activated are Rho, ERK, PLC, Rac. S1PR3 expression is localized to myocytes 
and perivascular smooth muscle cells, thus S1PR3 exhibits effects on the cardiovascular system, 
regulating bradycardia and hypertension (Strub et al., 2010). The rank order of compound 
potency for bradycardia is more closely aligned with the potency for activation of S1PR3 than the 
other S1P receptors (Forrest et al., 2004) The S1P3 receptor is the primary receptor coupling to 
PLC and the activation of this receptor also results in bradycardia (Means & Brown, 2009). 
1.5.6. S1PR4/S1PR5 
 S1PR4 and S1PR5 are also known as EDG6 and EDG8, respectively. As compared to 
other receptors, the localization of S1P4-5 is rather restricted, with predominant expression 
limited to human leukocytes, Natural Killer cells, airway smooth muscle cells and white matter 
of CNS tracts. S1P4 is primarily expressed in lymphoid tissues, including the thymus, spleen, 
bone marrow, appendix, and peripheral leukocytes (Strub et al., 2010) This expression pattern 
suggests potential roles of S1P4 in the immune system. In vivo roles and functions of S1P4 are 
still unknown (Ishii et al., 2004). Expression of S1P5 is restricted to specific tissues: brain, 
spleen, and peripheral blood leukocytes in human and brain, skin, and spleen in rat and mouse 
(Ishii et al., 2004). S1PR5 is highly expressed in oligodendrocytes suggesting its potential roles 
in maturation and myelination of oligodendrocytes S1PR4 couples with Gi/o, Gs, and G12/13, 
whereas S1PR5 couples with Gi/o and G12/13. 
1.5.6. Intracellular targets of S1P 
 For many years, the myriad of effects of S1P on cellular function have been attributed to 
downstream signaling elicited by the five well-known and extensively studied Gprotein-coupled 
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S1P receptors. However, a number of effects of S1P cannot be explained by this receptor family, 
raising the possibility that S1P also binds to and modulates the function of intracellular targets.. 
For example, organisms such as Dictyostelium discoideum, Sacharomyces cerevisiae and 
Arabidopsis thaliana do not express S1PR but display cellular responses to S1P (Yester et al., 
2011). Discrepancies are also found in mammalian systems. Dihydro-S1P and S1P bind and 
activate S1PRs with similar affinities (Chun et al., 2002), but dihydro-S1P, which is rapidly 
dephosphorylated in the cytosol, does not mimic all of the actions of S1P. For example dihydro-
S1P, although a good substrate for S1PR1 in situ, does not cause significant ceramide 
accumulation or increase apoptosis (Le Stunff et al., 2002) and, does not have any significant 
cytoprotective effect (Van Brocklyn et al., 1998). For example, S1P, but not dihydro-S1P, 
protects male germ cells from apoptosis, an effect that was linked to inhibition of NF-κB and 
activation of Akt (Suomalainen et al., 2005). On the contrary, S1P-phosphonate, which does not 
bind to S1PRs, still protects Swiss 3T3 fibroblasts cells from apoptosis (Van Brocklyn et al., 
1998). Furthermore, microinjection of S1P appears to increase DNA synthesis independent of G 
proteins (Van Brocklyn et al., 1998).  
 The identity of intracellular binding sites for S1P is only beginning to emerge. 
Cytoplasmic and subcellular targets identified to date include histone deacetylases (HDACs) 
(Hait et al., 2009) this study showed that, HDACs are direct intracellular targets of S1P and link 
nuclear S1P to epigenetic regulation of gene expression. S1P was shown to be a missing cofactor 
for the E3 ubiquitin ligase TRAF2 and that TRAF2 was a novel intracellular target of S1P  
Interestingly, only S1P, and not dihydro-S1P, which lacks the double bond in S1P, was shown to 
bind to and activate TRAF2 (Alvarez et al., 2010). β-site amyloid precursor protein cleaving 
enzyme-1 (BACE1) was shown to be another site in neurons to which S1P bound. S1P also 
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specifically bound to BACE1 in vitro and increased its proteolytic activity, suggesting that 
cellular S1P directly modulates BACE1 activity (Takasugi et al., 2011). In these studies 
inhibition or downregulation of SphK1 and SphK2, or overexpression of S1P-degrading enzymes 
all decreased BACE1 activity and Aβ production (Maceyka et al., 2012). These responses were 
mediated by intracellular S1P independently of its cell surface G-protein-coupled receptors. Also 
prohibitin 2 PHB2, a highly conserved protein that regulates mitochondrial assembly and 
function, was recently shown to bind S1P in vitro and in vivo (Maceyka et al., 2012;Strub et al., 
2011;Yester et al., 2011). PHB2 localizes predominantly to the inner mitochondrial membrane 
where it is thought to form a large, macromolecular complex with PHB1 that is involved in 
mitochondrial biogenesis and metabolism (Takasugi et al., 2011;rtal-Sanz & Tavernarakis, 2009) 
By targeting monomeric PHB2 (but not closely related PHB1), S1P is implicated in the 
regulation of proper assembly and function of cytochrome-c oxidase of the mitochondrial 
respiratory chain in cardiac myocytes (Strub et al., 2011). Moreover, PHB is reported to reduce 
mitochondrial free radical production and oxidative stress in brain injury models, perhaps by 
stabilizing the function of complex I (Zhou et al., 2012). Binding of S1P to PHB2 and its action 
on mitochondrial function represent a potential novel link between intracellular S1P binding and 
ICl,swell, an ion channel activated by ROS.  
1.6. FTY720, an S1PR agonist 
FTY720 is an immunomodulating drug, approved for treating multiple sclerosis. This 
agent modulates S1PR function and was highly effective in Phase II clinical trials for recurring 
multiple sclerosis (MS) (Kappos et al., 2006). FTY720 displays structural similarity to S1P and 
efficacy as an immunosuppressant in models of autoimmune disease and in solid organ 
24 
 
 
 
transplantation. However, this sphingosine analog is a prodrug that must be phosphorylated in 
vivo by SphK2 (Zemann et al., 2006) to form its active form, FTY720-phosphate (FTY720-P) 
(Albert et al., 2005;Brinkmann et al., 2002), that binds to four of the five G protein-coupled S1P 
receptor subtypes (Brinkmann, 2007). There are differences in the affinity of FTY720-P 
conformers for S1PRs. (S)-FTY720-P, but not (R)-FTY720-P or the parent FTY720, acts as a 
full agonist at S1PR1 (EC50 = 0.3 nM), S1PR4 (0.6 nM) and S1PR5 (0.3 nM), with ~10-fold lower 
affinity for S1PR3 (3.1 nM), but is inactive at S1P2 (>10,000 nM) (Albert et al., 2005;Brinkmann 
et al., 2002;Mandala et al., 2002). The differing receptor affinities and potencies of FTY720-P 
and S1P suggest they might induce distinct responses in vivo, either by G protein-coupled 
signaling or byfunctional antagonism upon internalization of S1P receptors (Brinkmann, 2009). 
FTY720 has shown to have effects on heart as well. FTY720 slows spontaneous heart 
rate due to activation of the G protein-gated K+ channel IK,ACh (GIRK) activation in mouse atrial 
myocytes (Koyrakh et al., 2005). Although FTY720 is well-tolerated in humans, it produces a 
transient mild to moderate bradycardia (Schmouder et al., 2006). This bradycardia may be due to 
FTY720-induced activation of IK,ACh in sino-atrial node, which would slow phase 4 
depolarization, shift maximum diastolic potential to a more negative voltage, and shift threshold 
potential to a more positive voltage. Furthermore, FTY720 prevents ischemia-reperfusion (I/R) 
injury and I/R-associated arrhythmias. This cardioprotective effect of FTY720 is thought to 
result from activation of the Pak1 pathway (Egom et al., 2010). Moreover, in diabetic heart up-
regulation of S1PR1 by FTY720 contributes to its agonist action, and FTY720 exerts functional 
antagonism by stimulating translocation of S1PR3 from the plasmalemmal to the kinase C (PKC) 
(Brinkmann et al., 2002). Furthermore, FTY720, preferentially distributes into HDL and inhibits 
the development of atherosclerotic lesions in LDLR-/- mice on a cholesterol-rich diet (Nofer et 
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al., 2007). These effect are mediated via S1PR. Although FTY720 did not change HDL or total 
cholesterol levels or the lipoprotein profile, it protected against the development of 
atherosclerosis (Nofer et al., 2007). In addition, FTY720 was shown to effectively reduce the 
progression of atherosclerosis in apolipoprotein E-deficient mice on a high-cholesterol diet (Yin 
et al., 2012;Tolle et al., 2007). 
1.7. Role of S1P in cardiac physiology and pathology 
 Heart disease is the leading cause of death in the United States. Alteration in lipid 
metabolism leading to pathological changes in cardiovascular system has been studied 
considerably, and lipid metabolites with beneficial effects on the heart also have been identified. 
The sphingolipid metabolites regulate the function of heart by acting as second messengers to 
activate various signaling pathway, and alterations in sphingolipid metabolism are implicated in 
many cardiovascular diseases, including congestive heart failure, atherosclerosis, and 
ischemia/reperfusion injury (Karliner & Brown, 2009).  
 Sphingolipid, especially ceramide and S1P are known to accumulate in various cardiac 
diseases (Chatterjee et al., 2006;Levade et al., 2001). Sphingolipids are implicated to have effect 
on cardiac function at the level of signal transduction. Both SphK1 and SphK2 are expressed in 
cardiac myocytes (Kohama et al., 1998). Also three of the five known GPC S1PR1-3 are 
expressed in heart. Figure 4 shows the action of the three S1P receptors in heart, with their 
respective Gprotein coupling and downstream effect on the heart function (Means & Brown, 
2009). The differential expression of these receptors may contribute to differential cellular 
responses (Anliker & Chun, 2004;Ishii et al., 2004). 
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Figure 4: S1P receptor signaling in the heart(Means & Brown, 2009). For 
cited references, see Means, 2009.  
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In cardiac myocytes, the expression pattern is: S1PR1 > S1PR3 >  S1PR2 (Zhang et al., 
2007;Means et al., 2008). The pattern is similar in vascular endothelial cells, but S1PR2 levels 
are very low: S1PR1 > S1PR3 ≫ S1PR2. In contrast, cardiac fibroblast S1PR3 expression is the 
highest and S1PR2 expression is minimal, whereas  aortic smooth muscle cells have the highest 
expression of S1PR2 (Means & Brown, 2009;Alewijnse et al., 2004). 
 The cardiovascular effects of S1P signaling include hypertrophy, cardioprotection 
(Karliner et al., 2001;Zhang et al., 2007), mobilization of calcium, and effects on ion channels 
and contractility (Sugiyama et al., 2000a;Sugiyama et al., 2000b). Acting on the fibroblast, S1P 
mediates migration and proliferation, which are required for fibrosis and important in remodeling 
(Gellings et al., 2009;Takuwa et al., 2013). Additionally S1P can modulate vascular 
permeability, angiogenesis, and vascular tone (Chae et al., 2004;Wymann & Schneiter, 
2008;Visentin et al., 2006). In the blood, S1P circulates bound to high density lipoprotein 
(HDL). S1P offers cardio-protective effects by inhibiting endothelial cell apoptosis, converging 
with the cardioprotective effects of HDL (Chatterjee et al., 2006;Keul et al., 2007). In contrast, 
pro-atherogenic properties of S1P have also been cited (Keul et al., 2007).  
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1.7.1. S1P and Cardioprotection 
S1P is known to be involved in cardioprotection in both the intact heart and isolated cardiac 
myocyte models of ischemia and hypoxia (Karliner et al., 2001). Exogenously applied S1P 
enhanced the nenonatal rat cardiomyocyte survival during hypoxia (Karliner et al., 2001). 
Similarly, S1P produced intracellularly by SphK in response to FM ganglioside had similar 
cardioprotection in response to hypoxia (Karliner et al., 2001). Identical effect is observed in 
adult mouse ventricular myocytes models, and various S1PR1 and S1PR3 agonist and antagonist 
elicited predictable protective effect from hypoxia. These actions are attributed to activation of 
the PI3K signaling pathway, leading to activation of Akt and inhibition of GSK-3β (Zhang et al., 
2007). Similar to pharmacological approaches, knockout of sphingosine kinase 1 suggested that 
S1P protects the heart against hypoxic injury during glucose deprivation (Tao et al., 2007). 
 Identical to studies in isolated cardiac myocytes, S1P was shown to be protective against 
I/R injury in intact heart. Both exogenous S1P and S1P generated by the stimulation of SphK 
activity offered cardioprotection against ischemic injury which was measured by cardiac 
function such as LVDP or creatine kinase release (Vessey et al., 2008). Whereas the protection 
afforded by exogenous S1P administration was demonstrated to occur through a PKCε 
independent pathway (based on studies with PKCε knockout mice), protection afforded by 
intracellularly generated S1P required PKCε (Jin et al., 2007). Levkau's group showed protection 
of heart against damage from 30 min ischaemia/24 h reperfusion following exogenous S1P 
administration (Keul et al., 2007). Although it has been argued that S1PR1 mediates 
cardioprotection against I/R injury (Karliner, 2004), based on studies with the specific S1PR1 
agonist SEW2871, however the role of other S1PR cannot be excluded (Tsukada et al., 2007). 
There have been contradicting data about which receptors are involved in offering 
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cardioprotection. Means et. al. claims that, S1PR2 and S1PR3-mediated Akt activation protects 
against in vivo myocardial ischemia-reperfusion injury (Means et al., 2007). This contradicts 
with Karliner's group which suggests the role of S1PR1 instead. 
1.7.2. S1P and Cardiac Electrophysiology 
 Sphingolipids are known to regulate the activity of several ion channels, both cation and 
anion channels, found in cardiac myocytes. For example, the voltage-dependent K+ (Kv) channel, 
Kv2.1, is activated by the action of SMase D, which splits off choline from sphingomyelin and 
shifts the voltage-dependence of Kv2.1 activation negative by about ~30 mV; in contrast, SMase 
C, which removes the negatively charged phosphodiester as well as choline, suppresses Kv2.1 
current by 90% in a voltage-independent fashion (Ramu et al., 2006). Both SMase C and D 
strongly suppress the anion current carried by CFTR (Ramu et al., 2007)). Ceramide a metabolite 
of sphingolipid, also modulates cardiac ion channels. The HERG (KCNH2) K+ channel that 
underlies the rapid component of the delayed rectifier current, IKr, is down regulated by 
ceramide, an effect attributed to reduction of surface expression following protein ubiquitylation 
and lysosomal degradation (Chapman et al., 2005)}. In contrast, membrane permeant C2-
ceramide inhibited HERG without altering membrane expression, but HERG inhibition was 
reversed by antioxidants and the superoxide dismutase mimetic MnTBAP, which converts O2-• to 
H2O2 (Bai et al., 2007). Findings with C2-ceramide suggested O2-• was responsible for inhibition 
of HERG in the experimental model. Also modulaton of gating HERG by C6-cermaide has been 
attributed by the translocation of the channel within lipid rafts (Ganapathi et al., 2010). Ceramide 
also suppresses L-type Ca2+ channel current in ventricular myocytes (Schreur & Liu, 1997). 
Furthermore, our laboratory found that ceramide activated ICl,swell in ventricular myocytes, but 
this was attributed to the metabolism of ceramide rather than this lipid itself (Raucci & 
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Baumgarten, 2009;Raucci & Baumgarten, 2010;Raucci et al., 2010). The metabolic product of 
ceramide, S1P is also known to modulate various ion channel. S1P mediates both chronotropic 
and inotropic effects in the heart. Very early studies suggested S1P stimulates muscarinic 
receptor-activated inward rectifier K+ current (IK,ACh). The S1P induced current was inhibited by 
pertusis toxin suggesting a role of S1PR (Bunemann et al., 1995). Furthermore, a different study 
in freshly isolated guinea pig, mouse, and human atrial myocytes suggested that S1P-induced 
IK,ACh activation by the S1PR3 (Himmel et al., 2000). This action is attributed to activation of 
S1PR3 receptors and, as the antagonist of the receptor suramin, blocked these effects. However 
suramin is a G protein inhibitor which acts by preventing nucleotide exchange (Beindl et al., 
1996;Keul et al., 2007;Nanoff et al., 2002). Thus the receptor subtype cannot be confirmed by 
the effects of suramin. Also activation of IK,ACh by S1PR3 is thought to explain S1P-induced in 
bradycardia in mice and humans (Sanna et al., 2004) .However work from Landeen et.al 
demonstrated that IK,ACh can contribute to the negative inotropy following S1P activation of 
S1PR1 (perhaps through Giβγ subunits in mice) (Landeen et al., 2008). Moreover, recent work 
utilizing heterologously expressed receptors, human atrial myocytes, and phase I clinical trial 
data also argues that S1PR1 rather than S1PR3 is largely responsible for S1P-induced activation 
of IK,ACh and bradycardia in man and attributes the discrepancy with previous analyses to 
species-specific effects (Gergely et al., 2012). FTY720, an S1PR agonist, mimics effects of S1P 
by activating IK,ACh (Koyrakh et al., 2005). S1P slows down the pacemaker activity of the 
sinoatrial node cells in vitro and in vivo in majority of models, including human (Ochi et al., 
2006;Guo et al., 1999). The chronotropic effects of S1P also are exhibited in mouse ventricular 
myocytes, where it causes cell shortening (Means et al., 2008). Recently studies in anesthetized 
and conscious rats administered with two clinically tested S1P agonists, FTY720 or BAF312, 
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suggest that S1PR1 mediates bradycardia while hypertension is mediated by S1PR3 activation 
(Fryer et al., 2012). 
S1P also antagonizes the effect of isoproterenol-induced increase in cAMP and positive 
inotropy (Landeen et al., 2008). These studies were done using the pharmacological agents 
SEW2871 agonist for S1PR1 and VPC23019 antagonist for S1PR1&3, S1PR1 receptor plays a 
predominant role in mediating the negative inotropic effects in mouse ventricular myocytes 
(Landeen et al., 2008). However, the role of other the two S1P receptors cannot be ruled out. 
 Sphingolipids have been implicated in regulation of chloride channel in cardiac muscle, 
(d'Anglemont de Tassigny et al., 2003). SMaseD induces inhibition of CFTR current, thereby 
modulating Cl− channel in chronic inflammatory diseases (Ramu et al., 2007). Furthermore it 
was demonstrated that ceramide inhibits CFTR-activity of the apical membrane (Ito et al., 2004). 
In cultured keratocytes isolated from wounded rabbit corneas, S1P activates a lysophosphatidic 
acid (LPA)-activated Cl− current that outwardly rectifies with a physiologic Cl− gradient (Wang 
et al., 2002). Although the authors claimed the current was the volume-sensitive Cl− current, they 
did not demonstrate volume-sensitivity nor provide the pharmacological or biophysical evidence 
necessary to distinguish between Cl− channels. In xenopus oocytes, both S1P and LPA activate 
an oscillatory Ca2+-activated Cl− current by receptor-dependent release of Ca2+ from an IP3-
sensitive site (Noh et al., 1998).  
1.8. S1P and ROS signaling 
 Sphingolipid signaling is known to produce ROS in response to various stimuli. S1P 
generates ROS production in response to elevated transmural pressure in ex vivo model of 
isolated resistance vessels, from skeletal muscle. The initial elevation in ROS was entirely 
dependent on the activation of NADPH oxidase,(Keller et al., 2006). Moreover S1PR1 protein 
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expression is increased in cultured bovine aortic endothelial cells response to exogenous H2O2 
without an alteration in mRNA levels (Igarashi et al., 2007). Hence there could be a possible 
feedback response modulating ROS production by S1P receptors. There have been reports of 
S1PR1 mediated activation of ROS signaling, that regulates the egress of both hematopoietic 
progenitors and BM stromal cells (Golan et al., 2012). There have been studies where SphK is 
responsible for NOX production in neutrophils. This NOX production is shown to be Ca2+ store 
depletion-dependent SphK activation (Schenten et al., 2011). Similarly in human leukemia cell 
line, inhibitor of SphK, DMPS, was responsible for apoptosis, and ROS were the critical 
regulators of caspase-8-mediated apoptosis in DMPS-treated leukemia cells (Kim et al., 2009). 
 There is growing evidence that the sphingolipids also play a role in the cellular response 
to oxidative stress. I/R injury leads to ROS generation and apoptotic cell death, and ceramide 
generation has been implicated in mediating cell death in response to ROS in a variety of tissues, 
including liver (Llacuna et al., 2006), brain (Ohtani et al., 2004), and heart (Bielawska et al., 
1997). In the heart, I/R rapidly activates neutral sphingomyelinases in a ROS-dependent manner. 
In cardiomyocytes, there are two primary sources of ROS: NADPH oxidase (NOX) and the 
mitochondrial electron transport chain (ETC). Evidence shows that S1P can activate ROS 
production via NOX and increases H2O2 production in murine fibroblasts (Catarzi et al., 2011). 
This response was PI-3K- and PKC-dependent and was similar to PDGF-induced NOX 
activation, and both S1PR1 and S1PR3 receptors and Gi signaling were involved. During hypoxia 
and pre-conditioning an increased mitochondrial ROS production is associated with 
sphingolipids, in experimental models in Fibroblastic L-cells (Lecour et al., 2006). Furthermore, 
a similar increase in mitochondrial ROS is observed in a heart failure model (Lecour et al., 
2006;Llacuna et al., 2006). Studies in SphK1 transgenic mice suggested that chronic activation 
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of SphK1-S1P signaling results in both pathological cardiac remodeling through ROS mediated 
by S1PR3 activation and favorable cardioprotective effects (Takuwa et al., 2010). 
 Furthermore, sphingolipid signaling cascades overlap significantly with modulators of 
ICl,swell. ICl,swell is known to be spontaneously activated in various model of heart diseases. Also 
ROS is the key regulator of ICl,swell. Thus sphingolipid signaling is likely to play an important 
role in stimulating ROS production and activating ICl,swell in a number of cardiovascular diseases. 
Thereby sphingolipid can act as effector molecules mediating cardiac function in 
pathophysiological conditions.  
1.9. HL-1 cells as a potential tool to investigate ICl,swell   
 HL-1 cells are an immortalized murine atrial cell line derived from a primary culture of 
SV40 large T antigen-induced atrial tumors. This cell line may be repeatedly passaged while 
maintaining its contractile, morphological and electrophysiological characteristics (Claycomb et 
al., 1998). Studies utilizing a variety of genetic, immunohistochemical, electrophysiological, and 
pharmacological techniques have demonstrated that HL-1 cells possess many of the features of 
adult atrial cardiomyocytes and are a useful experimental tool. For example, cardiac muscle cell 
structure and function have been assessed in HL-1 cells (McWhinney et al., 2000), and calcium 
handling was studied using the three ryanodine receptor (RyR) mutations associated with stress-
induced ventricular tachycardia in humans (George et al., 2003). Electrophysiological studies in 
HL-1 cells characterized the delayed rectifier K+ current (IKr), (Claycomb et al., 1998;Akhavan 
et al., 2003), L- and T-type Ca2+ currents (Xia et al., 2004), and pacemaker current (Sartiani et 
al., 2002). HL-1 cells also have been used to study the cardiac response to pathological states, 
including hypoxia (Nguyen & Claycomb, 1999;Cormier-Regard et al., 1998), 
ischemia/reperfusion injury (White et al., 2004;Ruiz-Meana et al., 2006), apoptosis (Kim et al., 
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2003;Carlson et al., 2002), and rapid pacing-induced electrical remodeling (Yang et al., 2005). 
The rennin-angiotensin system machinery is expressed in HL-1 cardiomyocytes, and exogenous 
Ang II modulates  L-type Ca2+ channels via a NOX-dependent pathway (Tsai et al., 2008;Tsai et 
al., 2007). Moreover, preliminary data from this laboratory demonstrates that ICl,swell is present in 
HL-1 myocytes and is regulated by ET-1 signaling and by ROS generated by NOX and 
mitochondria in a similar manner to native cardiomyocytes (Deng et al., 2010c). Furthermore, 
our preliminary studies showed that S1P activated ICl,swell in HL-1. Because this cell line would 
be amenable to molecular approaches initially considered, we decided to define the S1P 
signaling pathway responsible for the activation of ICl,swell in the HL-1 cell model. 
1.10. The objective of the present study 
 The objective of this study were the following (1) to determine the signaling mechanisms 
utilized by S1P to activate ICl,swell in heart either via GPC-S1PR or via intracellular binding site, 
and (2) whether S1P activates ICl,swell, a ROS-activated current, by triggering ROS production by 
NOX, mitochondria or both. This work extends earlier studies in the laboratory demonstrating 
that SMase C and ceramide activate ICl,swell (Raucci & Baumgarten, 2009). These studies 
demonstrated SMase-induced current is also suppressed by DCPIB, which under conditions that 
isolate anion currents is a specific inhibitor of ICl,swell. SMase-induced ICl,swell was inhibited by 
ebselen, a membrane permeant glutathione peroxidase mimetic that breakdowns H2O2 to H2O. 
Thus, the role of ROS was demonstrated as a modulator of SMase-induced activation of ICl,swell. 
Preliminary data from our laboratory using whole cell patch clamp recording showed that 
exogenous S1P (500 nM, 10 min) activated outwardly rectifying Cl- current with a reversal 
potential near ECl. This current was fully inhibited by addition of DCPIB (10 μM, 10 - 12 min) in 
the continued presence of S1P. Sphingosine is converted to S1P by the action of SphK. The 
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Sphingosine kinase inhibitor DL-threodihydrosphginosine (10 μM, 15 – 20 min) fully inhibited 
bacterial SMase-induced ICl,swell. Thus SMase induced production of sphingosine does not get 
converted to S1P due to the use of inhibitor of SphK. Thus, S1P rather than upstream 
sphingolipids must be responsible for the observed effects of SMase C and ceramide on ICl,swell. 
Moreover previously it is demonstrated that SMase-induced Cl− current is mediated by ROS 
(Raucci & Baumgarten, 2009). Furthermore, the source of ROS modulating ICl,swell in response to 
exogenous S1P application was tested. As found for the SMase-induced Cl− current, the 
activation of ICl,swell by S1P was completely inhibited by rotenone (10 μM, 15 – 20 min) a 
mitochondrial Complex I inhibitor. However, in contrast to SMase-induced ICl,swell, addition of 
apocynin (500 μM, 10 min) inhibitor of NADPH oxidase, in the continued presence of S1P 
partially reduced the S1P-induced Cl− current. The following aims were addressed in this study 
SphK/S1P pathway and cardiac G protein coupled S1P receptors (S1P1-3) modulate the activity 
of ICl,swell. S1P receptor signaling modulates ICl,swell by ROS production via either NADPH 
oxidase, mitochondria or both. Furthermore the aim of this study was to test if S1P elicits ICl,swell 
via its binding to intracellular target(s) or plasmalemmal S1P receptors. 
 
 
 
36 
 
Chapter 2 MATERIALS and METHODS 
 
 
 
 
2.1 Culture of HL-1 cardiomyocytes 
HL-1 cardiac myocytes passage 69-89, an immortalized mouse atrial cell line (Claycomb 
et al., 1998), were used for the studies. Tissue culture dishes were first coated with a gelatin 
(Becton-Dickinson 214340) (0.02%)/fibronectin (Sigma F1141 comes as 1 mg/ml) (0.5%) 
mixture (3 mL in 60 x 15 ml mm dishes) and incubated overnight at 37°C. HL-1 cells were 
cultured in pre-coated dishes using Claycomb medium (Sigma-Aldrich 51800C) supplemented 
with 10% fetal bovine serum (Sigma-Aldrich, F2442), 100 μg/mL penicillin/streptomycin 
(Cellgro 30-002-CI), 0.1 mM norepinephrine (Sigma-Aldrich A0937), and 2 mM L-glutamine 
(Invitrogen/Life Technologies, 25030-081). The cells were kept at 37°C in an atmosphere of 5% 
CO2 and 95% air at a relative humidity of approximately 95%. Once the cells reached 
confluence, they were passaged in a 1:3 split. To split the HL-1 cells, they were briefly rinsed 
with Dulbecco’s phosphate buffered saline without Ca2+ or Mg2+ (DPBS; Quality Biological 
QBI14057101) and then incubated with 0.05% trypsin/0.481 mM EDTA-Na2  
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(2 mL for 60 x 15 ml10 mm dish; Life Technologies, 25300120 & 25200056, respectively) at 
37°C for 2 min until the cells dissociated from the flask surface. Double the amount of soybean 
trypsin inhibitor (25 mg/100 mL DPBS; Life Technologies, 17075029) was added directly to 
flask, and then the contents were transferred to a 15 mL centrifuge tube. The cells were 
centrifuged at 1100 rpm for 5 min, the supernatant was removed by aspiration, and the pellet was 
gently resuspended in 3 mL of supplemented Claycomb medium and incubated for 1 hour. For 
culture preparation, the cells were transferred to gelatin/fibronectin-coated dishes. For 
electrophysiological studies, the cells were spun after an hour incubation, the supernatant media 
removed and the pellet re-suspended in 5 ml of 1T bath solution. 
2.2. Experimental solutions and drugs 
 Bath and pipette solutions were designed to isolate the Cl- current. Isosmotic bath 
solution (1T; 300 mOsm/kg; T, times isosmotic) contained (in mM): 90 N-methyl-Dglucamine-
Cl, 3 MgCl2, 10 HEPES, 10 glucose, 5 CsCl, 0.5 CdCl2, 70 mannitol (pH 7.4, adjusted CsOH). 
Hyperosmotic bath solution (1.5T, 450 mOsm/kg) had the same composition except for an 
additional 150 mM mannitol, and hypoosmotic bath solution (0.85T, 255 mOsm/kg) contained 
60 mannitol. Pipette solution contained (in mM): 110 Cs-Aspartate, 20 TEA-Cl, 5 Mg-ATP, 0.1 
Tris-GTP, 0.15 CaCl2, 8 Cs2-EGTA, 10 HEPES (pH 7.1, adjusted with CsOH). To make 
symmetrical Cl− pipette solution, 82 mM CsCl replaced an equal amount of Cs-aspartate. 
Osmolarity was verified by freezing-point depression. 
 Stock solutions of D-erythro-sphingosine-1 phosphate in methanol (S1P; 1 mM, 
Cayman), FTY720 in ethanol (FTY; 0.5 or 10 mM, Cayman), SEW2871 in DMSO (SEW; 10 
mM, Cayman), VPC23019 in DMSO (VPC; 130 nM or 13 µM, Tocris), CAY10444 or BML-
241 in DMSO (CAY; 1 or 10 mM, Tocris), and DCPIB (20 mM; Tocris) in DMSO purged under 
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argon were frozen (−20°C) in aliquots until use.  Gallein (10 mM, Tocris) in DMSO, stored at 
(−20°C) in alliquots until use, Rotenone (20 mM, Sigma-Aldrich). The NADPH oxidase 
inhibitor gp91ds-tat, a membrane permeant fusion peptide, was synthesized by the Tufts 
University Core Facility, and stocks  in 150 mM NaCl plus 10 mM acetic acid were frozen (–
20°C) in aliquots until use. 
2.3. Whole cell patch clamp and electrophysiological recordings 
HL-1 cells were scattered on a glass-bottomed chamber and placed on the stage of an 
inverted light microscope (Nikon) with Hoffman modulation optics, and a high resolution video 
camera (CCD72; Dage-MTI) was used to visualize individual cells. Cells were suprafused with 
bath solution at 2−3 mL/min, and recordings were made at room temperature (22–23°C). Pipettes 
were pulled from 7740 thin-walled borosilicate capillary tubing (Sutter) and were fire polished to 
a final tip diameter of approximately 3 µm with a resistance in bath solution of 2 – 4 MΩ. 
Membrane currents were recorded in the whole-cell configuration using an Axopatch 200B 
amplifier and Digidata 1322A data acquisition system (Axon). A 3-M KCl agar bridge served as 
the ground electrode. Seal resistances of 2 – 10 GΩ typically were obtained, and membrane 
capacitance routinely was measured. All membrane potential data were corrected for the 
measured liquid junction potential, and myocytes were dialyzed with pipette solution for 3-5 min 
prior to the start of recording. Voltage clamp protocols and data acquisition were controlled by 
pClamp 8.2 (Axon). Successive 500-ms voltage steps were implemented from a holding potential 
of −60 mV to test potentials ranging from −100 to +60 mV in +10 mV increments. Membrane 
currents were low-pass filtered at 2 kHz and digitized at 5 kHz. Representative current traces 
were low-pass filtered at 500 Hz for presentation, and the displayed I-V curves are from the 
39 
 
 
 
corresponding current traces. To minimize variability, experiments were designed to use cells as 
their own controls.  
2.3.1. Intracellular application of agents:  
 In some cases, S1P and FTY720 were delivered via the patch pipette. In these studies, 
pipettes first were dipped in drug-free solution for 60 s, taking up a ~1 mm column of solution 
by capillary action. Then, the pipettes were backfilled with drug-containing media, and whole 
cell recordings were begun within ~2 min. Therefore, the initial traces were obtained under 
control condition, and the cell served as its own control. 
 The claim that diffusion of S1P (MW 379.5 Da) and FTY720 (MW 343.9 Da) were slow 
enough for the cells to serve as its their control is supported by the fact that the current was 
stable before drug-induced current activation. This assertion is also supported by numerical 
estimates.  Einstein’s classic theory of diffusion arising from Brownian motion and the Stokes-
Einstein equation consider spherical solute particles that are much larger than their solvent (for 
detailed discussion, see (Hille, 2001;Crank, 1975)). Their analysis found that the diffusion 
coefficient, D, is inversely proportional to r3, where r is the radius of the solute, and that r is 
proportional to M, the solute’s molecular weight. Using glucose (MW 180 Da; observed D = 6.8 
× 10-6 cm2/s; (Finch, 1995).) as an index, the inverse cubic relationship between MW and D 
suggests that D for S1P and FTY720 should be 5.31 and 5.48 × 10-6 cm2/s, respectively, similar 
to the observed D of 5.2 × 10-6 cm2/s for cellobiose (MW 342 Da) (Finch, 1995). In a 1-
dimensional system, as approximated by the nearly parallel sides of the pipette tip, the root 
mean-square diffusion distance, rrms, equals (2Dt)1/2. Thus, the time required for S1P or FTY720 
to diffuse ~1 mm through the column of drug-free media is 942 and 912 s, or 15.7 and 15.2 min, 
respectively. These calculations should be regarded only as estimates, however. First, S1P and 
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FTY720 are not spherical and may remain associated with their hydrophobic solvent in pipette 
solution; both will alter D. Second, the height of the column is an estimate, and bulk flow during 
backfilling the pipette may have reduced the drug-free column height. Third, the time calculated 
here is for the rrms drug concentration, and the “leading edge” of diffusion is faster. Nevertheless, 
the calculations suggest that the diffusion time for these agents is likely to be long compared to 
the time require to make a seal and begin recording, confirming the idea that the cell can be used 
as its own control. 
2.4 Western Blots 
2.4.1 Protein extraction for western blots  
 HL-1 cells were grown to 90% confluence, and the media was removed by aspiration. 
The dish was then rinsed with 10 mL of ice-cold PBS. Next, ice-cold RIPA cell lysis buffer (200 
µL) was added [RIPA lysis buffer: 25 mM TRIS-HCl (pH 7.5), 150 mM NaCl, 1% NP-40 
(detergent solution), 1 mM Na3VO4, and 1× Protease Inhibitor Cocktail (Sigma-Aldrich; 
P2714)]. To dislodge and break the cells, RIPA lysis buffer was repeatedly pipetted slowly. The 
resulting lysate was transferred into 2 ml Eppendorf tube, and was again pipetted 15-times. The 
cell lysis solution was then sonicated on ice for 10 s to break the cells apart. Next, the lysate was 
subject to centrifugation at 12,000 × g in a pre-cooled centrifuge for 15 min. The supernatant was 
immediately transferred to a fresh centrifuge tube, and the pellet was discarded. Protein 
concentration as determined with a BCA protein assay kit (Thermo Scientific; 23227), and the 
sample was divided into aliquots and stored at -80OC for further use. 
 
41 
 
 
 
2.4.2 Immunoblotting for S1PRs 
 Total protein (30 μg) was loaded into 10% Bis-Tris polyacrylamide electrophoresis gels 
(Life Technologies) and after electrophoresis was subsequently transferred to a nitrocellulose 
membrane (Life Technologies). After the transfer, membranes were blocked for 2 h at room 
temperature in blocking buffer [Tris buffered saline plus Tween-20 (TBS-T); 10 mM Tris, 
150mM NaCl, 0.1 % Tween-20, pH 7.5 with 10 % instant non-fat dried milk. The membrane 
was then incubated overnight at 4ºC in the same buffer with antibody, polyclonal rabbit anti-
S1PR1-3 (1:500; Santa Cruz’ sc-25489, sc25491, sc-30024). The following day, membranes were 
washed four times for 10 min in TBS-T, blocked for 30 min, and subsequently incubated for 1 h 
in secondary antibodies using goat anti-mouse IgG-HRP (1:10,000; Santa Cruz; sc-2004). After 
four 10-min washes in TBS-T and two 10-min washes in TBS, immunodetection of S1PR 
protein was accomplished using an ECL system and X-ray film (exposure, 1-5 min). The 
following day, the membranes were stripped, blocked for 30 min at room temperature in Tris-
buffered saline plus TBS-T with 3% instant non-fat dried milk and incubated for 2.5 h at room 
temperature in the same buffer with polyclonal, rabbit, anti-cyclophilin A (1:5,000; Millipore, 
07-313). Membranes were then washed three-times for 10 min in TBS and subsequently 
incubated for 1 h in secondary antibodies using goat anti-rabbit IgG-HRP (1:5,000; Rockland, 
611-1302). After three 10-min washes in TBS-T and two ten-min washes in TBS, 
immunodetection of cyclophilin-A protein was accomplished using an ECL system (exposure, 1-
5 min).  
2.4.3. Densitometry:  
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 Densitometric analysis was used to quantify S1PR protein expression levels by 
determining the ratio of intensity of each band relative to that of goat anti-rabbit cyclophilin-A, 
which was used as a loading control. Analysis  was done using Quantity One software and the 
VersaDoc Imaging System (BioRad). 
2.5 Statistics 
 Summary patch clamp data are reported as mean ± SEM; n denotes the number of cells. 
Mean currents are expressed as current density (pA/pF) to account for differences in myocyte 
surface membrane area, and selected paired comparisons are expressed as a percentage or as the 
intervention-induced difference current. Statistical analysis was executed using SigmaStat 3.11 
(Systat). For multiple comparisons, a One-Way or a One-Way Repeated Measures ANOVA was 
performed followed by a Holm-Sidak test for all pair wise comparison. Non-linear curve fits 
were done in SigmaPlot 10.0 (Systat) using the Hill equation. In case of comparing the current 
densities of two independent groups, unpaired t test were used. In all case, P < 0.05 was taken as 
significant. 
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Chapter 3 Results 
 
 
 
 
3.1. Exogenous sphingosine-1-phosphate activates a Cl− current resembling ICl,swell in HL-1 
cardiac myocytes 
As shown in Figure 5, sphingosine-1-phosphate (S1P; 500 μM, 5 – 10 min), a bioactive 
sphingolipid molecule, activated an outwardly-rectifying Cl− current with a reversal potential 
near the Cl− equilibrium potential (ECl), −43 mV , under isosmotic conditions. S1P increased 
current at +60 mV by 3.84 ± 0.87 pA/pF (n = 17, P <0.001), from 1.48 ± 0.18 to 5.32 ± 1.06 
pA/pF, and a S1P-induced current was observed in >60% of the cells tested. Addition of DCPIB 
(10 μM, 5-10 min), a highly selective ICl,swell blocker (Decher et al., 2001), inhibited the S1P-
induced Cl− current by 113 ± 8% (n = 5, P < 0.001) in the continued presence of S1P, and there 
was no significant difference between the DCPIB-inhibited and control currents (n = 5). The 
greater than 100% block of S1P-induced current by DCPIB suggests that there may have been a 
small amount of basal activation of the current under control condition, as previously reported in 
adult myocytes (Baumgarten & Clemo, 2003;Sorota, 1992).One of the characteristic property of 
ICl,swell is that it is outwardly rectifying under both physiological as well as symmetrical chloride 
gradients, distinguishing it from other Cl- currents, such as CFTR, that exhibit linear current 
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voltage relationships with a symmetrical chloride gradient (Hume et al., 2000). S1P-induced 
current was outwardly rectifying under symmetrical as well as physiological chloride solutions.  
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Figure 5: Sphingosine-1 phosphate (S1P) elicited a Cl− current in HL-1 atrial cardiac 
myocytes that resembled ICl,swell. (A) Families of currents under control conditions (Ctrl), and 
after treatment with 500 nM [S1P]out for 10 min, and after addition of DCPIB (+DCPIB; 10 μM, 
5 min) in the continued presence of S1P. Each cell was used as its own control; holding 
potential, −60 mV; test potentials, −100 to +60 mV. (B) Current-voltage (I-V) relationships for A; 
cell capacitance, 15.8 pF. (C) Current densities at +60 mV. S1P increased Cl− current by 3.84 ± 
0.87 pA/pF (n = 14, P < 0.001). The S1P-induced current was inhibited by 113 ± 8% (n = 5, P < 
0.001) by the ICl,swell-specific inhibitor DCPIB. One-way repeated measures ANOVA and Holm-
Sidak test were used for all pairwise comparison. 
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Figure. 6 shows the response to exogenous S1P when Cl- was 100 mM in both bath and 
pipette solutions (i.e., symmetrical). The Cl- current elicited by S1P (500 nM) continued to 
outwardly rectify. Thus, the S1P-induced current showed both outward rectification under 
physiological and symmetrical Cl- conditions and block by DCPIB. These features are diagnostic 
for ICl,swell.   
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Figure 6: Sphingosine-1-phosphate (S1P) elicited a Cl− current in HL-1 atrial 
cardiac myocytes in symmetrical chloride solution. (A) Families of currents under 
control conditions (Ctrl), and after treatment with 500 nM [S1P]out for 10 min, and after 
addition of DCPIB (+DCPIB; 10 μM, 5 min) in the continued presence of S1P. Cl− 
concentrations: bath, 100 mM; pipette, 100 mM. (B) I-V relationships for A. (C) Current 
densities at +60 mV. S1P increased Cl− current by 12.01 ± 2.21 pA/pF (n = 4, P < 0.001). 
The S1P-induced current was inhibited by 104 ± 18% (n = 4, P < 0.001) by DCPIB. The 
mean current shown in C represents the unpaired comparison of the data. However the 
percent values of inhibition by DCPIB is derived from paired analysis, where the cell is 
used as its own control.  
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3.2. Role of G protein coupled-S1P receptors  
 Most of the actions of S1P are mediated by its binding to G protein-coupled S1P 
receptors (Means & Brown, 2009;Karliner & Brown, 2009). S1P is produced inside cells by the 
action of sphingosine kinases, and it is transported out of cells via ABC cassette binding proteins 
known as ABC transporters. S1P then acts as a ligand for a family of five G protein-coupled 
receptors, termed S1PR1-5, formerly called endothelial differentiation gene (EDG) receptors. 
Three (S1P1-3) out of the five receptors are present in heart (Means & Brown, 2009).  
3.2.1 S1P receptor agonists elicit ICl,swell  
 Previous work in our laboratory demonstrated that the G protein-coupled angiotensin II 
AT1 receptor, the endothelin ETA receptor, and the epidermal growth factor EGF receptor 
activate ICl,swell in response to osmotic swelling and mechanical stretch (Browe & Baumgarten, 
2004;Ren et al., 2005;Browe & Baumgarten, 2005;Browe & Baumgarten, 2006). To test the 
hypothesis that S1P also activated ICl,swell via G protein coupled receptors, we initially made use 
of receptor agonists. SEW2871, a small heterocyclic compound, and FTY720, an S1P analog, are 
agonists of the S1PR1 (Tsukada et al., 2007) and S1PR1&3 (Brinkmann et al., 2002;Brinkmann, 
2009), respectively. If S1P1 and/or S1P3 are involved in the activation of ICl,swell, by S1P, these 
compounds should act as mimetics and also activate the current As shown in Figure 7, SEW2871 
(SEW; 1 μM, 5 – 10 min), activated an outwardly-rectifying Cl− current with a reversal potential 
near ECl under isosmotic conditions. Current at +60 mV increased by 2.69 ± 0.62 pA/pF (n = 5, P 
<0.001), from 1.98 ± 0.38 to 4.66 ± 0.1 pA/pF.  
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Figure 7 SEW2871, a selective agonist for S1PR1, elicited ICl,swell. (A) Families of 
currents under control conditions (Ctrl), and after treatment with 1 µM exogenous 
SEW2871 (SEW) for 10 min, and after addition of DCPIB (+DCPIB; 10 μM) in the 
continued presence of SEW. (B) I-V relationships for A. (C) Current densities at +60 
mV. SEW increased Cl− current from 1.98 ± 0.38 to 4.66 ± 0.1 pA/pF (n = 5, P < 
0.001). DCPIB inhibited SEW-induced current by 103 ± 12%.  
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Addition of DCPIB (10 μM, 5-10 min), a highly selective ICl,swell blocker, inhibited the 
SEW-induced Cl− current by 103 ± 12 % (n = 5, P < 0.001) in the continued presence of SEW, 
and there was no significant difference between the DCPIB-inhibited and control currents. 
Because SEW2871 is a selective S1PR1 agonist (Tsukada et al., 2007), these data are consistent 
with the idea that G protein-coupled S1PR and specifically S1PR1 was responsible for the 
activation of ICl,swell by exogenous S1P. 
FTY720 (FTY), an S1PR1&3 agonist, is used as an immunosupressor in the treatment of 
multiple sclerosis (Kappos et al., 2006). Based on the response to exogenous SEW2871, an 
S1PR1 agonist, we predicted that exogenous FTY720 also would activate ICl,swell. The literature 
indicates that 100 nM exogenous FTY720 ([FTY]out) is sufficient to activate S1PR1&3 and their 
downstream signaling targets (Egom et al., 2010;Forrest et al., 2004;Yin et al., 2012), including 
IK,ACh in cardiac myocytes (Fryer et al., 2012;Koyrakh et al., 2005). As shown in Figure 8, 
however, 100 nM [FTY]out (10 min) failed to activate ICl,swell under isoosmotic condition. To 
verify that the channels responsible for ICl,swell were present, 100 µM H2O2, was added to the 
same cells in the continued presence of FTY. H2O2 previously was shown by our lab to activate 
ICl,swell under isoosmotic conditions and acts downstream in the signaling cascade (Ren et al., 
2008;Deng et al., 2010c). Despite their insensitivity to 100 nM [FTY]out, ICl,swell in the same 
cells was activated by 100 µM H2O2, confirming the expression of the channels underlying this 
current. Moreover, increasing the applied concentration 10-fold to 1 μM [FTY]out also failed to 
significantly evoke ICl,swell (n = 3, P = 0.338 data not shown). 
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Figure 8: Exogenous FTY720, an agonist for S1PR1&3, failed to activate ICl,swell 
(A) Families of currents under control conditions (Ctrl), and after treatment with 100 
nM [FTY]out for 10 min, and after addition of H2O2 (100 μM) in the continued 
presence of FTY. (B) I-V relationships for A. (C) Current densities at +60 mV. FTY 
failed to activate significant current under isosmotic conditions. In the same cells, 
H2O2 (100 µM) increased Cl− current from 1.72 to 5.15 ± 1.71 pA/pF (n = 4, P < 
0.001) demonstrating that the ICl,swell was expressed and could be activated by a 
downstream effector. 
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 Figure 9 illustrates the response to 10 μM [FTY]out, a 100-fold higher concentration 
than that nominally required to activate G protein receptor-coupled signaling. At this very high 
concentration, [FTY]out increased ICl,swell, from 0.93 to 4.30 ± 0.39 pA/pF at + 60 mV (n = 4, P 
< 0.001), and the FTY-induced current was completely blocked by DCPIB (101 ± 8%). Thus, 
although exogenous FTY720 was able to elicit ICl,swell, the action of this agent appeared to have 
an exceptionally low potency compared to other published measures of FTY720-induced S1P1&3 
signaling. 
FTY720 is a prodrug and must be taken up, phosphorylated by intracellular SphK2 to its 
active phosphorylated form, FTY720-P, and then exported via an ABC transporter before it can 
reach plasmalemmal S1PR that face the extracellular environment (Brinkmann, 2007). Once 
phosphorylated and exported, FTY720-P can bind to and activate all of the G protein-coupled 
S1PR except S1PR2. This raised the possibility that uptake, phosphorylation or export of 
FTY720 were defective. When exogenous FTY720 was applied, such defects might substantially 
lower the concentration of FTY720-P at the cell membrane surface and, thereby, both might 
significantly reduce the G protein receptor-dependent signaling necessary to evoke ICl,swell and 
the potency of exogenous FTY720. If this was the case, exogenous application of FTY720-P 
should bypass the postulated defects and should potently elicit ICl,swell under isosmotic 
conditions, as was observed with both exogenous S1P and the S1PR1 agonist SEW2871. To the 
contrary, 100 nM [FTY-P]out also failed to significantly activate ICl,swell. (n = 3, P = 0.104 data 
not shown). Moreover, Figure 10 shows a comparison of FTY-P 100 nM vs. FTY-P 10 µM. 
FTY-P (100 nM) activated significantly less current, 1.90 ± 0.34 pA/pF, than FTY-P (10 µM), 
4.92 ± 0.97 pA/pF. There was no statistical difference between current activated at Ctrl 
conditions vs. [FTY-P]out (100 nM)-induced current (not shown). However there was statistical  
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Figure 9: FTY720, a selective agonist for S1PR1&3, elicited ICl,swell. (A) Families of currents 
under control conditions (Ctrl), and after treatment with 10 µM [FTY]out for 10 min, and after 
addition of DCPIB (+DCPIB; 10 μM) in the continued presence of FTY. (B) I-V relationships 
for A. (C) Current densities at +60 mV. FTY increased Cl− current from 0.93 to 4.30 ± 0.39 
pA/pF (n = 14, P < 0.001). DCPIB inhibited FTY-induced current by 101 ± 8% (n = 4). 
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difference between the current activated by [FTY-P]out (10 µM).vs. control as shown in Figure 
13. where FTY-P (10 µM) increased the current from 1.77 to 4.92 ± 0.61 pA/pF (n = 5, P < 
0.001). This argues that failure of the uptake, phosphorylation of FTY720 or export of FTY720-
P are not sufficient to explain the observed insensitivity to FTY720 and FTY720-P. 
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Figure 10: Extracellular FTY-P- (100 nM) vs. FTY-P (10 µM)- induced 
current. Comparison of ICl,swell current density with FTY-P (10 µM, 10 min) (n 
= 5) applied outside of myocytes elicited significantly greater ICl,swell than 
FTY-P (100 nM) (n = 5) in the two groups of cells (P = 0.036). FTY-P (100 
nM) activated significantly less current, 1.90 ± 0.34 pA/pF, than FTY-P (10 
µM), 4.92 ± 0.97 pA/pF. Mann-Whitney Rank Sum Test was utilized for 
statistical analysis. There was no statistical difference between current 
activated at Ctrl conditions vs. [FTY-P]out (100 nM)-induced current (not 
shown). However there was statistical difference between the current 
activated by [FTY-P]out (10 µM).vs. control as shown in Figure 13. Where 
FTY-P (10 µM) increased the current from 1.77 to 4.92 ± 0.61 pA/pF (n = 5, 
P < 0.001). 
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3.2.2 Inconsistencies in block of S1P- and FTY720-induced activation of ICl,swell by 
nominally specific S1P receptor antagonists. 
The ability of exogenous S1P and a high concentration of exogenous FTY720 to activate 
ICl,swell under isosmotic conditions raised the possibility that S1PR are involved in signaling 
pathway that evoked channel activation but could not simply explain the low potency of FTY720 
nor the insensitivity to FTY720-P. To further explore the role of S1PR, we determined whether 
well-defined SIPR antagonists had their expected effects on S1P- and FTY720-induced ICl,swell 
activation. Exogenous S1P is expected to stimulate all three cardiac S1PR (S1PR1-3), whereas 
exogenous FTY720 is expected to stimulate only S1PR1&3.  
First, we examined the action of CAY10444 (CAY), a selective antagonist for S1PR3 in 
the presence of [S1P]out. CAY10444 is a selective antagonist of S1P binding to the S1PR3 
receptor. For example, CAY strongly suppresses reduced S1PR3-dependent S1P-induced calcium 
increase in HeLa cells (Pyne & Pyne, 2011). Also CAY inhibits, increase in intracellular calcium 
mediated by P2 receptor or α1A-adrenoceptor stimulation in CHO cells and reduces α1A-
adrenoceptor stimulated contraction of mesenteric artery by acting on S1PR3.(Jongsma et al., 
2006). As seen in Figure 11, in the presence of 500 nM extracellular S1P, CAY (10 µM, 10 min) 
inhibited the S1P-induced current by 90 ± 10%. These data are consistent with the notion that 
S1P elicits ICl,swell by acting a ligand for S1PR3 and, thereby, triggering a signaling pathway that 
is responsible for fully activating the current. On the other hand, we expect that S1P also will 
have activated S1PR1, and previously we showed that an S1PR1 agonist, SEW, activated ICl,swell. 
Such effects via S1PR1, should not have been abrogated by a CAY, a selective S1PR3 antagonist.  
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Figure 11: CAY10444, a selective antagonist for S1PR3, blocked S1P-induced 
ICl,swell. (A) Families of currents under control conditions (Ctrl), and after treatment with 
500 nM [S1P]out for 10 min, and after addition of CAY10444 (+CAY; 10 μM) in the 
continued presence of extracellular S1P. (B) I-V relationships for A. (C) Current 
densities at +60 mV.  S1P increased the current from 1.46 to 5.43 ± 0.67 pA/pF (n = 5, 
P < 0.001). S1P-induced current was blocked 90 ± 10% by CAY, and current after 
block was not significantly different than the Ctrl.  
 
  
58 
 
 
 
To further test whether S1PR1 and/or S1PR3 modulate ICl,swell, we utilized VPC23019 
(VPC), an antagonist for S1PR1&3 (Davis et al., 2005). Contrary to the expectation, VPC (13 µM, 
10 min) failed to block the S1P-induced current. Figure 12 shows that [S1P]out-activated 
outwardly rectifying chloride current under isoosmotic conditions and that  VPC had no effect on 
ICl,swell in the continued presence of S1P. Nevertheless, the S1P-induced current was completely 
blocked by DCPIB in the presence of VPC, confirming that the current activated by S1P was 
ICl,swell.  
The next step was to test the role of these antagonists in the presence of the agonist 
S1PR1&3 , FTY720. CAY which blocked the [S1P]out-induced current, failed to block the current 
activated by FTY720. These inconsistencies could be attributed to the conformational change 
imparted by FTY on the receptors and therefore inability of CAY to block the current. 
Nonetheless other site of action of FTY could not be excluded.  
Next we tested whether the action of antagonists on FTY720-P induced current was 
consistent with S1PR actions. As seen in Figure 13, FTY720-P (10 µM, 10 min) activated ICl,swell 
under isoosmotic condition. CAY10444 (10 µM, 10 min), a selective antagonist for S1PR3, 
failed to block the FTY-elicited current despite the fact that CAY10444 fully inhibited the S1P-
induced current (see Fig. 11). The FTY-P-induced current was completely blocked by DCPIB in 
the presence of CAY, however, showing it was ICl,swell. In addition, we tested whether the 
S1PR1&3 antagonist. VPC23019 (13 µM, 10 min) affected the response to extracellular FTY 
(Figure 14). As seen with CAY (in response to [FTY-P]out) (Fig. 13), VPC also failed to inhibit 
the [FTY]out induced current. 
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Figure 12: VPC23019, a selective antagonist for S1PR1&3, failed to block S1P-induced 
ICl,swell (A) Families of currents under control conditions (Ctrl), and after treatment with 500 
nM [S1P]out for 10 min, and after addition of VPC23019 (+VPC; 13 μM) in the continued 
presence of extracellular S1P. (B) I-V relationships for A. (C) Current densities at +60 mV. 
S1P increased the current from 1.55 to 9.34 ± 1.48 pA/pF (n = 4, P < 0.001). VPC failed to 
block S1P-induced current. S1P-indcued current was inhibited 102 ± 11%, by DCPIB. 
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Figure 13: CAY10444, a selective antagonist for S1PR3, failed to block [FTY-P]out-
induced ICl,swell. (A) Families of currents under control conditions (Ctrl), and after 
treatment with 10 µM [FTY-P]out for 10 min, and after addition of CAY10444 (+CAY; 10 
μM) in the continued presence of FTY-P. (B) I-V relationships for A. (C) Current densities 
at +60 mV.  FTY-P increased the current from 1.77 to 4.92 ± 0.61 pA/pF (n = 5, P < 0.001). 
CAY failed to block FTY-P-induced current, whereas the FTY-P-induced current was 
inhibited 81 ± 16%, by DCPIB. 
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Figure 14: VPC23019, a selective antagonist for S1PR1&3, failed to block [FTY]out-
induced ICl,swell. (A) Families of currents under control conditions (Ctrl), and after treatment 
with 10 µM [FTY]out for 10 min, and after addition of VPC23019 (+VPC; 10 μM) in the 
continued presence of FTY. (B) I-V relationships for A. (C) Current densities at +60 mV. FTY 
increased the current from 1.70 to 13.73 ± 2.64 pA/pF (n = 4, P < 0.001). VPC failed to block 
FTY-induced current.  
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Taken together, the effects of putative S1PR agonists and antagonists cannot be explained 
by their nominal actions on S1PR and instead raise the possibility that the target(s) of S1P, 
FTY720, SEW and CAY that modulate ICl,swell are not the G protein-coupled S1P receptor family 
but rather distinct binding site(s). Alternatively, it has been proposed that S1PR might exist in 
different conformational states that regulate the affinity, potency, or efficacy of S1PR and 
thereby explain the unusual pharmacology of receptor ligands that could otherwise be interpreted 
as “off-target” effects (Pyne & Pyne, 2011). We have not tested the possibility that S1PR exist in 
alternative conformational states in HL-1 cardiomyocytes. 
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3.3. Intracellular vs. Extracellular S1P-induced current  
Most of the biological effects of S1P are explained by its action as a ligand for 
plasmalemmal G protein-coupled S1PR and the resulting activation of downstream signaling 
pathways. More recently, however, various intracellular binding targets for S1P have been 
recognized (Maceyka et al., 2012;Strub et al., 2011;Yester et al., 2011). Based on the observed 
inconsistencies in the regulation of ICl,swell by nominally S1PR selective agonists and antagonists, 
we considered the possibility that intracellular target(s) of S1P and its mimetics were responsible 
in modulating ICl,swell. To test this idea, we introduced S1P inside ([S1P]in). HL-1 myocytes via 
open tip of the patch pipette. Because the pipette contains a much larger volume than that of the 
myocyte, it effectively dialyze the cell, and as found for other mobile species, we expect that S1P 
in the pipette and cytosol will equilibrate As before, selected S1PR antagonists were utilized 
after exposure to S1P. Failure of S1PR antagonists to suppress current activation by [S1P]in 
would add support to the idea that S1P acted at intracellular targets rather than at extracellular 
S1PR after ABC transporter-mediated export.  
Figure 15 illustrates the results of applying 500 nM S1P inside the cell via the patch 
pipette. Because the first ~1 mm of the pipette tip was filled with S1P-free media and diffusion 
over this distance is slow (see Methods), control current was recorded immediately after 
breaking into the cell, and then, the current elicited by [S1P]in was obtained. [S1P]in activated 
an outwardly rectifying Cl- current that reversed near ECl. Addition of CAY (10 or 30 µM) to the 
bathing media during continued dialysis of the cytosol did not inhibit the [S1P]in-induced 
current. However, DCPIB blocked 94 ± 5% of the [S1P]in-induced current, implying the current 
was ICl,swell.  
64 
 
 
 
 
  
 
 
Figure 15: CAY10444, a selective antagonist for S1PR3, failed to block [S1P]in-
induced ICl,swell. (A) Families of currents under control conditions (Ctrl), and after 
treatment with 500 nM [S1P]in for 10 min, and after addition of CAY10444 (+CAY; 10 or 
30 μM) in the continued presence of [S1P]in. (B) I-V relationships for A. (Ctrl; filled circle, 
[S1P]in; open square, CAY 10 μM; open triangle, CAY 30 μM; inverted open triangle, 
DCPIB; filled diamond.) (C) Current densities at +60 mV. [S1P]in increased the current 
from 1.20 to 10.33 ± 1.75 pA/pF (n = 4, P < 0.001). The [S1P]in-induced current was not 
significantly blocked by 10 or 30 μM CAY (ns), but was blocked by DCPIB by 94.18 ± 
5.20% ( P < 0.001). Insensitivity of [S1P]in-induced current contrasts with its block of 
[S1P]out-induced current (see Fig. 10). DCPIB blocked current was significantly different 
from [S1P]in-induced current († ), but not different than control condition.  
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Figure 16: VPC23019, a selective antagonist for S1PR1&3, failed to inhibit [S1P]in-
induced ICl,swell. (A) Families of currents under control conditions (Ctrl), and after 
treatment with 500 nM [S1P]in for 10 min, and after addition of VPC23019 (+VPC; 13 μM) 
in the continued presence of S1P. (B) I-V relationships for A. (C) Current densities at +60 
mV.  S1P increased the current from 0.60 to 35.99 ± 11.99 pA/pF (n = 4, P < 0.001). VPC 
failed to block [S1P]in-induced current (ns).  
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The response to intracellular S1P application was contrary to findings with its extracellular 
application, where 10 µM CAY fully blocked the [S1P]out-induced current (see Fig. 11). The 
observation that CAY blocked the response to extracellular but not intracellular S1P excludes the 
possibility that pipette S1P acts on S1PR after its inside-out transport but is consistent with the 
notion that S1P elicits ICl,swell by acting on an intracellular target. Additionally, VPC23019, an 
S1PR1&3 antagonist, was unsuccessful in blocking the [S1P]in-induced ICl,swell (Fig. 16). This 
parallels the insensitivity of ICl,swell to VPC when S1P was applied in the bathing media (see Fig. 
14). Nevertheless, these data are also inconsistent with activation of ICl,swell via inside-out S1P 
transport and S1PR signaling. 
Compared to [S1P]out, [S1P]in activated a higher ICl,swell current density (pA/pF) when 
both were applied at 500 nM. Figure 17A shows that the S1P-induced current was 6.86 ± 1.27 
pA/pF for [S1P]out and 18.47 ± 4.42 pA/pF for [S1P]in (n = 14 each group, unpaired t test P = 
0.018). The greater response to [S1P]in than [S1P]out is contrary to expectations for S1P binding 
to extracellular facing S1PR. S1P applied via the patch pipette would need to equilibrate with the 
cytosol and then undergo inside-out transport to reach its presumed target, G protein-coupled 
S1PR. Therefore, one would predict a reduced response to [S1P]in or, if equilibration and inside-
out transport were very efficient, equal responses. 
It might be argued that [S1P]in or [S1P]out altered the ability of the cell to generate 
ICl,swell and, therefore current density, by a mechanism unrelated to binding the target responsible 
for S1P-induced current activation. To rule out this possibility, Figure 17B compares the 
responses of a subset of cells that underwent osmotic swelling (0.85T) in the presence of 500 nM 
[S1P]in or [S1P]out. In both cases, the current after osmotic swelling plus S1P was much larger 
than that after S1P alone (n = 5 for each group, P < 0.001 for each group) but was not  
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Figure 17: Intracellular vs. extracellular S1P and osmotic swelling-induced current.(A) 
Comparison of ICl,swell current density with S1P (500 nM, 10 min) applied inside or outside of 
myocytes. [S1P]in (n = 14) elicited significantly greater ICl,swell than [S1P]out (n = 14) in the 
two groups of cells (P = 0.018). [S1P]out (500 nM) activated significantly less current, 6.85± 
1.27 pA/pF, than [S1P]in, 16.55 ±4.42pA/pF, at same S1P concentration (B) Comparison of 
ICl,swell activated by osmotic swelling in 0.85T bath solution in the presence of S1P (subset of 
myocytes) in A. Currents after osmotic swelling were not significantly different (n = 6, for 
each group, ns). Note, change in scale for current density.  
 
  
68 
 
 
 
significantly affected by the location of S1P application (P = ns). This suggests that the number 
of functional ICl,swell channels and the components of signaling cascade that are activated by 
osmotic swelling were not differentially affected by intracellular versus extracellular S1P 
application. The very high ICl,swell current density after osmotic swelling recorded here is 
consistent with previous observations by our laboratory in HL-1 cardiomyocytes (Deng et al., 
2010c). 
In addition to evoking a higher ICl,swell current densities, [S1P]in activated the current with 
faster kinetics than [SIP]out, depicted in Figure 18. Typically, there was a lag of 3-4 min after 
switching the bath solution using a rapid flow system before ICl,swell activation by [S1P]out was 
apparent. With [S1P]in inside the pipette, the lag before ICl,swell activation began was only 1-2 
min. Similar differences in activation kinetics were observed in n = 6 [S1P]in and n = 10  
[S1P]out experiments. Furthermore the dose response relationship of [S1P]in as seen in Fig 19 
exhibits an half maximal current at 240 nM with Hill coefficient of 1.68. To avoid the variability 
from different passage number of cells, the dose response relationship was done in a subset of 
cells (cells grown on the same plate) for concentrations (30 nM, 100 nm, and 500 nM) [S1P]in. 
Based on the above results, this suggests S1P is more potent when applied inside the pipette vs. 
the extracellular application in the bath. 
The differences in activation kinetics and current density are opposite to that expected if 
S1P elicited ICl,swell via binding to G protein-coupled S1PR facing the bath solution. Bulk flow of 
the bath solution should result in the rapid delivery of S1P at its final concentration to S1PR. In 
contrast, S1P delivered via the patch pipette needs to be exported via the ABC transporters and 
then act in autocrine/paracrine manner on the plasmalemmal G protein-coupled S1PR. To the 
extent exported S1P diffuses across the unstirred layer at the plasmalemmal surface, it will be  
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Figure 18: Representative time course of activation of ICl,swell  by [S1P]out and [S1P]in. 
Intracellular application of S1P acted more rapidly and elicited a larger ICl,swell than 
extracellular application of S1P (500 nM for both). This is contrary to expectations if inside-
out transport of S1P and S1PR activation is required to evoke ICl,swell but is consistent with 
intracellular site(s) of action. Similar differences in kinetics were noted in n = 10  [S1P]in and 
n = 6 [S1P]out experiments.  
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Figure 19: Concentration-response relationship for [S1P]in. Current elicited by [S1P]in 
was measured at 30 (n = 3), 100 (n = 3), 225 (n = 3) and 500 nM (n = 6). Data were fit (solid 
line) with a sigmoidal curve with an EC50 of 240 nM, Hill coefficient of 1.68, and maximum 
current density of 15.4 pA/pF. The dose response relationship was done in a subset of cells 
(from same plate) for concentration (30 nM, 100 nm, and 500 nM). 
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washed away by bulk flow of S1P-free bath solution. This suggests that inside-out export of S1P 
during [S1P]in application will result in a lower S1P concentration at the receptors that achieved 
during [S1P]out application of the same concentration of S1P. Thus, if binding to plasmalemmal 
S1PR was responsible for the activation of ICl,swell, it seems likely that the current activated by 
500 nM [S1P]out would have faster activation kinetics and greater current density than that 
elicited by 500 nM [S1P]in.  
 To directly investigate the participation of G protein-coupled S1PR the activation of 
ICl,swell, we tested whether gallein, a pan Gβγ inhibitor. gallein, a cell-permeable xanthene 
compound that binds to Gβγ with high affinity (Kd ~400 nM derived from a surface plasma 
resonance binding study using Gβ1γ2) and blocks Gβγ-dependent cellular activities (Lehmann et 
al., 2008), affected the response to [S1P]out. The [S1P]out-induced current was not inhibited by 
gallein As seen in Figure 20, gallein (10 µM, 10  min) did not inhibit the [S1P]out-induced 
current. However, DCPIB blocked 115 ± 10% of the S1P-induced current verifying it was 
ICl,swell. These data argue that G protein-coupled receptors probably are not involved for the 
activation of ICl,swell by S1P but are consistent with the idea that S1P acts on intracellular binding 
site(s) and initiates a signaling pathway ultimately responsible for activating ICl,swell.  
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Figure 20: Gallein, a pan Gβγ inhibitor, failed to suppress [S1P]out-induced ICl,swell. (A) 
Families of currents under control conditions (Ctrl), and after treatment with 500 nM [S1P]out 
for 10 min, and after addition of gallein (+Gal; 10 μM, 10 min ) in the continued presence of 
S1P. (B) I-V relationships for A. (C) Current densities at +60 mV. S1P increased the current 
from 1.55 to 6.59 ± 1.0 pA/pF (n = 5, P < 0.001). Gal failed to block [S1P]out-induced 
current, but it was blocked by 115 ± 10% by DCPIB. 
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3.4. Intracellular vs. Extracellular FTY720  
FTY is identified as an agonist for plasmalemmal G protein-coupled S1PR1&3 and 
activates downstream signaling pathway at a concentration of 100 nM (Hofmann et al., 2009). 
However, we observed that a 100-fold higher concentration was required to activate ICl,swell (see 
Fig.10). Even the phosphorylated form, FTY720-P, required a 100-fold higher concentration that 
what is known to activate the S1PR (Hofmann et al., 2009) (see Fig.10 & 13). In addition, the 
S1PR antagonists VPC and CAY failed to block the [FTY]out-induced current (see Fig.13 & 14). 
Taken together, these data suggested that FTY720 acts on intracellular target(s) similar to S1P.  
To test the possibility that an intracellular target for FTY720 was responsible for eliciting 
ICl,swell, we introduced FTY720 inside the patch pipette ([FTY]in). Figure 21 compares the 
response of 100 nM [FTY]in to a 100-fold greater concentration, 10 µM, applied in bath solution 
([FTY]out). Although [FTY]in was at a 100-fold lower concentration, it evoked a 2-fold greater 
current (n = 20 for each group, unpaired t test P = 0.010). Furthermore, the kinetics of activation 
of ICl,swell was much faster with [FTY]in than [FTY]out, as depicted in Figure 22. Activation of 
current was not obvious for more than 4 min after applying FTY via the bath solution. With FTY 
inside the pipette, the lag before current activation was about 1 min, and a much larger current as 
turned on. Thus, the greater potency and faster time course of activation with [FTY]in than 
[FTY]out was even more striking than for [S1P]in and [S1P]out. These data argue that FTY is 
likely to elicit ICl,swell by binding to intracellular targets rather than to plasmalemmal S1PR.  
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Figure 21: Intracellular application of FTY activates a larger ICl,swell than extracellular 
application. (A) Comparison of current densities with 10 µM FTY (10 min) added to the bath 
solution ([FTY]out) and a 100-fold lower concentration, 100 nM (5 min),  included in the 
pipette solution ([FTY]in). [FTY]in elicited a significantly larger current (n for each = 20, P = 
0.010, unpaired t-test). As noted in section 3.2.1, 100 nM and 1 µM [FTY]out failed to evoke 
significant activation of ICl,swell. 
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Figure 22: Representative time course of activation of ICl,swell by [FTY]out and 
[FTY]in. Inclusion of 100 nM FTY in the patch pipette ([FTY]in) caused activation of 
ICl,swell to begin within 1 min of recording, whereas 10 μM FTY in the bath solution 
([FTY]out) turned on a smaller current more slowly. Similar results were observed with 
n = 12 [FTY]in and n = 8 [FTY]out experiments.  
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To test whether intracellular FTY was phosphorylated in the cytosol, underwent inside-out 
transport, and then bound to plasmalemmal S1PR, we used S1PR antagonists. As shown  in 
Figure 23, [FTY]in (100 nM, 10 min) strongly activated ICl,swell, but CAY did not inhibit the 
[FTY]in-induced current at either 10 or 30 µM. Nevertheless, the [FTY]in-induced current was 
blocked by 100 ± 21% by DCPIB, implying the current was ICl,swell. Furthermore, the S1PR1&3 
antagonist VPC23019 (13 µM, 10 min) also was unable to block the [FTY]in-induced current, as 
shown in Figure 24. Thus neither CAY nor VPC23019 suppressed the response to [FTY]in.  
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Figure 23: CAY10444, a selective antagonist for S1PR3, failed to block [FTY]in-induced 
ICl,swell. (A) Families of currents under control conditions (Ctrl), and after treatment with 100 
nM [FTY]in for 10 min, and after addition of CAY10444 (+CAY; 10 or 30 μM) in the continued 
presence of [FTY]in. (B) I-V relationships for A. (Ctrl; filled circle, [FTY]in; open squares, CAY 
10 μM; open triangle, CAY 30 μM; inverted open triangle, DCPIB; filled diamond.)(C) Current 
densities at +60 mV. [FTY]in increased the current from 1.46 to 9.42 ± 2.44 pA/pF (n = 4, P < 
0.001). Whereas CAY failed to inhibit the FTY-induced current, DCPIB reduced the current 
by 100 ± 21%.(P < 0.001). 
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Figure 24: VPC23019, a selective antagonist for S1PR1&3, failed to inhibit [FTY]in-
induced ICl,swell. (A) Families of currents under control conditions (Ctrl), and after treatment 
with 100 nM [FTY]in for 10 min, after addition of VPC23019 (+VPC; 13 μM, 10 min) in the 
continued presence of FTY, and after addition of rotenone (Rot; 10 µM, 20 min ), a 
mitochondrial complex I inhibitor.  (B) I-V relationships for A. (C) Current densities at +60 
mV. [FTY]in increased the current from 1.65 ±  to 7.32 ± 0.89 pA/pF (n = 4, P < 0.001). VPC 
failed to block [S1P]in-induced current, but rotenone (Rot)blocked FTY-induced current by 
109 ± 12% (P < 0.001).  
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3.5. Western Blot Analysis  
As mentioned previously S1PR are differentially expressed in different tissues, and 
studies in heart show that only S1PR1, S1PR2 and S1PR3 are expressed (Zhang et al., 
2007;Means et al., 2008). Hl-1 cells are an immortalized mouse atrial cell line. As discussed 
above, studies utilizing a variety of genetic, immunohistochemical, electrophysiological, and 
pharmacological techniques have demonstrated that HL-1 cells possess many of the features of 
adult atrial cardiomyocytes and are a useful experimental tool. However S1P receptors are not 
reported to date in this cell line. Given the inconsistencies in the action of the S1PR antagonist 
and lower potency of FTY720, we verified by immunoblotting that S1PR1-3 proteins were 
expressed in HL-1 cardiomyocytes, a point not previously established in the literature. Figure 25 
shows the expression of S1PR1-3 in HL-1 cardiomyocyte whole cell lysate and cyclophilin A 
used as control. On WB, the reaction products were seen with a molecular mass of about 42–47 
kDa in the whole cell lysate, which was consistent with the findings of S1PRs. Total protein (30 
μg) was loaded into 10% Bis-Tris polyacrylamide electrophoresis gels. Antibodies to S1PR1-3 
were used at a dilution of 1:500 (S1P1, rabbit polyclonal IgG Ab sc-25489; S1P2, rabbit 
polyclonal IgG Ab sc25491; S1P3, rabbit polyclonal IgG Ab sc-30024; Santa Cruz), and for 
cyclophilin A, at a dilution of 1:5,000 (rabbit polyclonal IgG Ab  07-313; Millipore). Detail of 
the western blot procedure is given in the Methods section. Various controls were implemented 
for this study including loading control to ensure equal loading of protein in each lane; 
cyclophilin A was used as the house keeping protein. Some extra bands were observed in 
addition to the band for S1PR1. One of the possible reasons for the multiple bands is non-specific 
binding of primary and secondary antibody. To rule out this possibility following controls were 
done. "No primary" control, the primary antibody was not added to one strip of membrane, and 
80 
 
 
 
only secondary antibody was added. The "no primary" indicates if any non specific binding or 
false positives bands due to non specific binding of the secondary antibody. This was done by 
using antibody dilution buffer containing no primary antibody. The secondary antibody was 
incubated on the sample in the same way as usual. Under these condition no bands were 
observed (data not shown), suggesting that there were no unspecific binding. One other control 
involved lowering the quantity of primary antibody concentration and increasing the number of 
washes. These intervention still showed extra band in addition to the band for S1PR1 (data not 
shown). The other possibility for extra band is presence of post-translational modifications with 
higher molecular weight proteins. This would require investigating the possibility of 
phosphorylation, glycosylation, acetylation, methylation or myristylation. For the 
immunoblotting studies we utilized polyclonal antibody, the polyclonal antibodies recognize 
several epitopes, and thereby show several bands.  
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Figure 25: Identification of S1PR1-3 protein expression in HL-1 myocytes. 
Representative Western blots for expression of S1PR1-3 and cyclophilin A were 
obtained from cell lysates under control condition. Antibodies to S1PR1-3 were used at 
a dilution of 1:500 (S1P1, rabbit polyclonal IgG Ab sc-25489; S1P2, rabbit polyclonal 
IgG Ab sc25491; S1P3, rabbit polyclonal IgG Ab sc-30024; Santa Cruz'), and for 
cyclophilin A, at a dilution of 1:5,000 (rabbit polyclonal IgG Ab  07-313; Millipore). 
Blots were done on 10% Bis-Tris polyacrylamide gels. For quantitative analysis, 
densities of the protein and for S1PR1-3 were normalized by their respective 
cyclophilin densities.  
        S1PR1                          S1PR2             S1PR3                
Cyclophilin A 
~45 KD 
82 
 
 
 
3.6. ROS mediates S1P and FTY720-induced activation of ICl,swell   
Previously the laboratory demonstrated that ROS are necessary downstream modulators 
in the regulation of ICl,swell by stretch, osmotic swelling, and other agents such as HIV protease 
inhibitors and ceramide (Browe & Baumgarten, 2004;Browe & Baumgarten, 2006;Ren et al., 
2008;Deng et al., 2010b;Raucci & Baumgarten, 2009). Osmotic swelling triggers ICl,swell via a 
signaling cascade that requires ROS production by NADPH oxidase followed by mitochondrial 
ROS production. In contrast, HIV protease inhibitors and, for example, inhibition of the 
mitochondrial electron transport chain at complex III by antimycin A, which causes ROS leakage 
to the cytosol, activate ICl,swell independent of NADPH oxidase. Therefore, we examined the role 
and source of ROS in S1P and FTY720-induced activation of ICl,swell.  
 As shown in Figure 24, 100 nM [FTY]in activated ICl,swell but VPC23019 failed to block 
the current. We next tested whether mitochondrial ROS production was required by blocking the 
electron transport chain at complex I with rotenone. Rotenone precludes electron transport to 
ROS leakage from complex III (Chen et al., 2003), and our laboratory previously showed that 
rotenone inhibits activation of ICl,swell by swelling, HIV protease inhibitors, antimycin A, and 
other interventions. Rotenone (10 µM, 20 min) blocked the FTY-induced current by 109 ± 12% 
(n = 4, P < 0.001) This suggests that [FTY]in triggers ICl,swell by stimulating mitochondrial ROS 
production and its leakage to the cytosol. To test whether ROS production by NOX was an 
upstream to mito ROS production, as found for swelling, stretch, and the G protein-coupled AT1 
and ETA receptors for angiotensin II and endothelin, respectively. And also to rule out the 
possibility that the presence of VPC affected the result for rotenone. In the presence of [FTY]in, 
we tested gp91ds-tat followed by rotenone. As seen in Figure 27, In the continued presence of 
FTY in the patch pipette, addition of gp91ds-tat (500 nM, 5 min) did not significantly affect 
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ICl,swell, but in contrast, addition of rotenone (10 µM, 20 min) abolished 86 ± 5 % of the current (n 
= 4, P < 0.001). Although the studies illustrated in Figures 24 and 27 demonstrate that 100 nM 
FTY720 applied inside the myocyte activate ICl,swell by augmenting mitochondrial ROS 
production, presumably from complex III, independent of NADPH oxidase ROS production, it is 
unclear whether the physiological effector, S1P, acts by the same mechanism. Figure 26 shows 
the effect of gp91ds-tat and rotenone, inhibitors of NADPH oxidase and mitochondrial ROS 
production, respectively, on the response to [S1P]in. First, myocytes were exposed to [S1P]in 
(500 nM, 5 min) to activate ICl,swell. In the continued presence of S1P in the patch pipette, 
addition of gp91ds-tat (500 nM, 5 min) did not significantly affect ICl,swell, but in contrast, 
addition of rotenone (10 µM, 20 min) abolished 96 ± 5 %. of the current (n = 5, P < 0.001) as 
seen in Figure 26. These data suggest that ROS production from mitochondria, independent of 
NADPH oxidase, is sufficient to activate S1P- and FTY720-induced ICl,swell.  
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Figure 26: S1P activated ICl,swell via mitochondrial ROS and, contrary to ICl,swell evoked 
by swelling or stretch, did not require ROS production by NADPH oxidase. ICl,swell 
elicited by pipette S1P (500 nM, 5 min) was blocked by suppressing mitochondrial complex I 
with rotenone (10 μM, 20 min), but not by gp91ds-tat (500 nM, 5 min), a fusion peptide 
inhibitor of NADPH oxidase. (A) Families of currents before and after treatment with S1P 
(500 nM, 5 min) and, then, after addition of gp91ds-tat and rotenone; (B) I-V relationships for 
A; (C) Current densities at +60 mV after S1P exposure and addition of gp91ds-tat and then 
rotenone in the continued presence of S1P (n = 5, P < 0.001). In contrast, the laboratory 
previously showed that osmotic swelling- and stretch-induced ICl,swell, which signal via AT1, 
ETa and EGF receptors, are fully blocked by both gp91ds-tat and rotenone, and 
mitochondrial ROS production is downstream from NADPH oxidase ROS production.  In 
contrast, S1P-induced ICl,swell, was not inhibited by gp91ds-tat but still was fully blocked by 
rotenone. 
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Figure 27: Intracellular FTY720 activated ICl,swell via mitochondrial ROS and, contrary to 
ICl,swell evoked by swelling or stretch, did not require ROS production by NADPH 
oxidase. ICl,swell elicited by pipette (100 nM, 5 min) FTY was blocked by suppressing 
mitochondrial complex I with rotenone (10 μM, 20 min) but not by gp91ds-tat (500 nM, 5 
min), an inhibitor of NADPH oxidase. (A) Families of currents before and after treatment with 
FTY720 and after addition of gp91ds-tat and rotenone. (B) I-V relationships for A. (C) Current 
densities at +60 mV after FTY exposure and addition of gp91ds-tat (n = 5, P < 0.01), and 
rotenone (n = 4, P < 0.001) in the continued presence of FTY. 
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This study demonstrated for the first time that both S1P and FTY720, a prodrug mimetic 
of S1P and agonist for S1PR1&3, activates a Cl− current with the biophysical and pharmacological 
properties of ICl,swell in immortalized HL-1 atrial myocytes. Furthermore, the selective S1PR1 
agonist SEW2871 also elicited ICl,swell. Rather than directly interacting with the channel, S1P and 
FTY720 evoke ICl,swell by augmenting mitochondrial ROS production. S1P- and FTY720-induced 
currents were fully suppressed by rotenone, a blocker of the mitochondrial electron transport 
chain at complex I, suggesting ROS generated by the Qo cite of complex III was responsible. 
Contrary to the signaling underlying activation of ICl,swell in cardiomyocytes in response to 
osmotic swelling, integrin stretch, angiotensin II, endothelin, and epithelial growth factor, ROS 
production by NADPH oxidase was not a required upstream effector. Moreover, based on 
inconsistencies in the responses to S1P agonists and antagonists and differences in the potency 
and kinetics of ICl,swell activation by intracellular and extracellular S1P, FTY720, and FTY-P, we 
propose that activation of mitochondrial ROS production and ICl,swell by these agents is due to 
binding to an intracellular ligand rather than to the well-known G protein-coupled S1PR that are 
expressed in cardiomyocytes, including HL-1 cells. Nevertheless, we cannot rigorously exclude a 
87 
 
 
 
role of S1PR in modulating the current. The proposed signaling pathway responsible for the 
activation of ICl,swell by S1P and FTY720 is shown in Figure 28. 
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Figure 28: Proposed model of ICl,swell regulation by S1P and FTY720. S1P and FTY720 
binding to intracellular site(s), perhaps mitochondrial prohibitin 2 (PHB2), triggers 
mitochondrial ROS production independent of NADPH oxidase and, thereby, activates ICl,swell. 
This model can explain the observed greater potency and faster kinetics of ICl,swell activation 
by S1P and FTY720 delivered to the cytosol via the patch pipette than via the bath  solution, 
insensitivity to FTY720-P, and apparent inconsistencies in the actions of well-described 
S1PR agonists and antagonists. S1P and FTY applied extracellularly can reach their 
intracellular ligands after uptake by ABC transporters (ABC). It seems likely that at least 
some nominally S1PR-specific agonists and antagonists also bind to intracellular S1P 
ligands that modulate ICl,swell with selectivity and affinities that have not yet been 
characterized. The possibility that S1PR also can modulate ICl,swell cannot be rigorously 
excluded, however. 
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4.1 Properties of S1P-, FTY720-, and SEW2871-induced Cl– current 
Sarcolemmal Cl– channels expressed in the heart include the cystic fibrosis 
transmembrane conductance regulator (CFTR) Cl− channel (ICFTR), Ca2+-activated Cl− channels 
(ICl,Ca), and ICl,swell (Hume et al., 2000), as well as an inwardly rectifying Cl− current attributed to 
ClC-2 (Duan, 2009). In the present study, we showed that S1P, FTY720, FTY720-P, and 
SEW2871 activated an outwardly rectifying Cl– current with properties that distinguish ICl,swell 
from other cardiac Cl– channels. We demonstrated that the Cl– current elicited by all four of 
these S1PR agonists was blocked by DCPIB. This ethacrynic acid derivative is the most selective 
anion channel inhibitor identified to date; DCPIB fully suppresses ICl,swell at 10 μM, the 
concentration used here, whereas CFTR, Ca2+-activated Cl− channels, and cardiac cation currents 
are insensitive to this agent (Decher et al., 2001). Another fundamental distinguishing 
characteristic of ICl,swell is its outward rectification with both physiological and symmetrical Cl– 
gradients (Hume et al., 2000;Baumgarten & Clemo, 2003;Sorota, 1994). In contrast, although 
ICFTR and ICl,Ca outwardly rectify with a physiological Cl– gradient, their I-V relationships are 
linear in symmetrical Cl– (Hume et al., 2000), and the ClC2 Cl– current inwardly rectifies in 
physiological Cl– (Duan, 2009). Thus, outward rectification of the S1P- and FTY720-induced 
current with both physiological and symmetrical Cl– gradients is strong biophysical evidence 
supporting the conclusion; the current is ICl,swell. In addition, as previously demonstrated for 
ICl,swell (Deng et al., 2010c;Baumgarten et al., 2011), the S1P- and FTY720-induced currents 
were triggered by mitochondrial ROS production, a regulatory pathway not reported for other 
cardiac anion channels. Finally, we focus here only on how these agents modulate Cl– channels 
because the experimental pipette and bath solutions were designed to suppress cation currents 
and the observed currents reversed at the expected Cl– equilibrium potential. Thus, the present 
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study demonstrated that S1P and its analogue FTY720 elicit ICl,swell under isosmotic conditions 
via production of mitochondrial ROS. Nevertheless, the molecular identity of ICl,swell remains 
elusive, and the mechanisms of ICl,swell inhibition by DCPIB is not understood.  
Sphingolipids have been shown to exert effects on cardiac ion channel function 
previously. For example, S1P mediates both a chronotropic as well as inotropic effects on the 
heart. S1P stimulates the muscarinic receptor-activated inward rectifier K+ current, IK,ACh, and 
this is attributed to the activation of S1PR3 receptors, as the antagonist of the receptor suramin, 
blocked these effects (Alewijnse et al., 2004;Himmel et al., 2000;Peters & Alewijnse, 2007). 
However suramin is a G protein inhibitor which acts by preventing nucleotide exchange rather 
than S1PR3 antagonist (Beindl et al., 1996;Nanoff et al., 2002;Yester et al., 2011). In addition, 
sphingolipids were implicated in the regulation of a Cl– channel in cardiac muscle, but the 
channel responsible was not identified (d'Anglemont de Tassigny et al., 2003). Previously our 
laboratory demonstrated that exposure to neutral Mg2+-dependent SMase C, which generates 
ceramide and phosphocholine by breaking down sarcolemmal sphingomyelinase, and exogenous 
C2-ceramide both activate ICl,swell in ventricular myocytes and suggested the response was due to 
S1P production and involved ROS (Raucci & Baumgarten, 2010). However, neither the 
signaling cascade activated by these sphingolipids nor the source of ROS were identified. CFTR 
also is regulated by sphingolipids. SMase D, which generates ceramide-1-P and choline, causes 
inhibition of CFTR current in whole oocytes injected with the CFTR cDNAs (Ramu et al., 
2007), and ceramide inhibits CFTR-activity of the apical membrane of Calu-3 cells (Ito et al., 
2004). Work on Kv channels showed gating is modified by direct interactions between 
membrane lipids and channel proteins (Ramu et al., 2006;Milescu et al., 2007). In addition, 
prolonged exposure to either C2-ceramide and SMase (>10 h) downregulates the hERG channel 
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by mechanisms involving ROS and ubiquitin-mediated degradation (Bai et al., 2007;Chapman et 
al., 2005). 
Although it is clear that S1PR agonists turned on ICl,swell, they did not fully activate the 
current. It previously was observed that osmotic swelling in 0.7T (T; times-isosmotic bath 
solution) gives full activation of ICl,swell in adult rabbit ventricular myocytes (Clemo et al., 1999), 
and 0.8T produces full activation in HL-1 cells myocytes (Deng et al., 2010c). We found, 
however, the magnitude of the current elicited by extracellular (~6.85 pA/pF) or intracellular 
S1P (~16.55  pA/pF) was much smaller than that observed after osmotically swelling HL-1 
myocytes with 0.85T bathing media (35-40 pA/pF). These differences may reflect a more modest 
stimulation of myocyte ROS production compared to that achieved with osmotic swelling or the 
participation of different signaling pathway. We did not directly measure HL-1 cell ROS 
production in the present studies.  
4.2 Do G protein-coupled S1PR elicit ICl,swell? 
S1P acts as a ligand for a family of five G protein-coupled receptors, S1PR1-5, which 
formerly were called endothelial differentiation gene (EDG) receptors (Chun et al., 2002). S1PR 
are differentially expressed in different tissues, and studies in heart show that only S1PR1, S1PR2 
and S1PR3 are expressed (Zhang et al., 2007;Means et al., 2008). The binding of S1P and 
FTY720-P to G protein-coupled receptors and the resultant downstream signaling pathways are 
thought to be largely responsible for the observed cardiac effects of both molecules (Means & 
Brown, 2009;Brinkmann et al., 2002); cf.,(Pyne & Pyne, 2011;Strub et al., 2010;Strub et al., 
2011). We verified by immunoblotting that S1PR1-3 proteins also were expressed in HL-1 
cardiomyocytes, a point not previously established in the literature.  
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 In addition to S1P, several other S1PR ligands turned on ICl,swell in HL-1 cardiomyocytes. 
We observed that ICl,swell was activated by SEW2871, a novel selective agonist for S1PR1 that is 
structurally unrelated to S1P (Sanna et al., 2004). Unlike S1P and FTY720, SEW2871 is a small 
heterocyclic lipophilic molecule that does not have a charged head-group. Activation of ICl,swell 
by a selective S1PR1 agonist lead to the prediction that FTY720, a sphingosine analog and 
S1PR1&3 agonist (Brinkmann, 2007) also would elicit ICl,swell. To the contrary, addition of 100 
nM FTY720 to the bathing media was ineffective, but exogenous H2O2 elicited ICl,swell in the 
same myocytes providing a positive control. Increasing the bath concentration of FTY720 to 1 
μM also failed to stimulate the current, but 10 μM was found to activate ICl,swell. This FTY720 
concentration is 100-fold greater than the 100 nM normally sufficient to fully activate S1PR1&3 
(Koyrakh et al., 2005).  
FTY720 is a prodrug that must be imported into cells by an ABC transporter, 
phosphorylated in situ by SphK2 (Zemann et al., 2006) to yield its active form, FTY720-P 
(Albert et al., 2005;Brinkmann et al., 2002), and then exported before it can bind to G protein-
coupled S1PR at the extracellular face of the cell membrane (Brinkmann, 2007). To exclude the 
possibility that defects in one or more of required steps explained the insensitivity to FTY720, 
we directly challenged the S1PR in HL-1 myocytes by adding FTY720-P to the bathing solution. 
Whereas 100 nM FTY720-P failed to activate current, ICl,swell was turned on by 10 μM FTY720-
P. Thus, like FTY720, the active phosphorylated form, FTY720-P, also had much lower than 
expected potency. In contrast, previous studies established (S)-FTY720-P [but not (R)-FTY720-P 
or parent FTY720] acts as a full agonist at S1PR1 (0.3 nM), S1PR4 (0.6 nM; not found in 
myocytes) and S1PR5 (0.3 nM; not found in myocytes) and with approximately a 10-fold lower 
potency at S1PR3 (3.1 nM), but it has no activity at S1P2 (>10,000 nM) (Albert et al., 
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2005;Brinkmann et al., 2002;Mandala et al., 2002). Therefore, 100 nM FTY720-P added to the 
bath should have fully activated both S1PR1&3 even if 100 nM and 1 μM FTY720 failed to 
generate and export sufficient FTY720-P in the present experimental system. Thus, although S1P 
and SEW2871 activated current at bath concentrations consistent with S1PR1 signaling, the 
exceptionally low potency of S1PR1&3 agonists FTY720 and FTY720-P argue against the idea 
that S1PR trigger ICl,swell. 
Studies with the S1PR antagonists CAY10444 (also known as, BML-241) and 
VPC23019 also raised doubts regarding the role of S1PR. CAY10444 is a selective and effective 
S1PR3 antagonist and in multiple cell line suppresses a variety of downstream effects (Waeber & 
Salomone, 2011). For example, 10 μM CAY10444 inhibits the prosurvival effect of HDL in a 
mouse cardiomyocyte hypoxia-reoxygenation model interfering with the PI3K-AKT signaling 
pathway, an effect attributed to block of S1PR3 (Tao et al., 2010). We observed a striking 
inconsistency with the action of CAY10444. First, the positive response to SEW2871, a selective 
S1PR1 agonist, suggests CAY10444 should fail to inhibit current. To the contrary, bath S1P-
induced current was fully blocked by 10 μM CAY10444, but bath FTY720-induced current was 
not affected, even after raising the CAY10444 concentration 3-fold. One might argue that full 
current activation can be evoked by either S1PR1 or S1PR3 signaling and that the failure of even 
high concentrations of CAY10444 to block the action of FTY720 was due to an inability to 
compete with the high bath FTY720 concentration (10 μM) needed to elicit the current. On the 
other hand, VPC23019, a potent S1PR1&3 antagonist, failed to suppress ICl,swell activated by both 
bath S1P (500 nM) and bath FTY720 (10 μM). If, in fact, stimulation of either S1PR1 or S1PR3 
signaling was sufficient to elicit ICl,swell, VPC23109 (13 μM) should have blocked the response to 
500 nM S1P; its Ki for displacing 32P-S1P is 7.86 and 5.98 for S1PR1 and S1PR3, respectively, in 
94 
 
 
 
HEK293T cells (Davis et al., 2005). To confirm the presence of ICl,swell in the antagonist-
insensitive myocytes, we demonstrated that DCPIB suppress the current in the same cells. Taken 
together, the response to these agonists and antagonists was inconsistent with the idea that S1P 
and FTY720 elicit ICl,swell simply by binding to G protein-coupled S1PR and evoking their 
signaling pathways.  
It is difficult, however, to rigorously exclude the possibility that "off target effects" and 
complex pharmacology might contribute to the discrepancy (Pyne & Pyne, 2011). In addition, 
VPC23019 is a phosphorylated lipid and is a potential substrate for lipid phosphate 
ectophosphatases (Pyne et al., 2005). Therefore, degradation of VPC23019 might have prevented 
its inhibitory action at S1P receptors. We did not test whether VPC23019 was hydrolyzed in the 
present experimental system. There also are reports of the internalization of the S1PR in 
response to the agonist (Gergely et al., 2012). If internalized S1PR are inaccessible to 
antagonists but continue to signal and support the activation of ICl,swell, receptor internalization 
might explain the failure of certain antagonist to block the response to agonists acting on S1PR.  
Signaling by heterotrimeric G proteins requires GDP/GTP exchange and the dissociation 
its α and βγ subunits upon ligand binding to the G protein-coupled receptor. The process is 
terminated by the hydrolysis of Gα-bound GTP by small GTPases, and then, the heterotrimeric 
complex reassembles. Therefore, S1PR-induced G protein signaling can be blocked by 
interrupting the G protein cycle or downstream pathways. We found, however, that 10 μM 
gallein, a pan βγ inhibitor failed to suppress the response to bath S1P. On the other hand, gallein 
binding to βγ (Kd, 422 nM; IC50, 241 nM) suppresses G-protein signaling-induced PI-3K and 
RAC1 activation and ROS production in HL6 cells and primary human neutrophils (Lehmann et 
al., 2008). This argues against the involvement of G protein-coupled S1PR in ROS-dependent 
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activation of ICl,swell. Nevertheless, to confirm the conclusion that G protein signaling does not 
play a role in ICl,swell activation by S1PR agonists, it would be useful to suppress signaling with 
additional small molecule inhibitors or molecular methods.  
4.3 Intracellular targets of S1P : Potential role in activating ICl,swell.  
 Rather than acting at S1PR, an alternative possibility is that S1P, FTY720, its 
phosphorylated analogue FTY720-P, and other S1PR agonists such as SEW activate ICl,swell by 
binding to intracellular ligands. Recently identified intracellular targets include HDACs, E3 
ubiquitin ligases, and prohibitin-2 (PHB2). One of the study showed that, HDACs are direct 
intracellular targets of S1P and link nuclear S1P to epigenetic regulation of gene expression (Hait 
et al., 2009). S1P was shown to be a missing cofactor for the E3 ubiquitin ligase TRAF2 and that 
TRAF2 was a novel intracellular target of S1P. Interestingly, only S1P, and not dihydro-S1P, 
which lacks the double bond in S1P, was shown to bind and activates TRAF2.(Alvarez et al., 
2010). β-site amyloid precursor protein cleaving enzyme-1 (BACE1) was shown to be another 
site in neurons to which S1P binds. S1P also specifically bound to BACE1 in vitro and increased 
its proteolytic activity, suggesting that cellular S1P directly modulates BACE1 activity (Takasugi 
et al., 2011). In these studies inhibition or downregulation of SphK1 and SphK2, or 
overexpression of S1P-degrading enzymes all decreased BACE1 activity and Aβ production 
(Maceyka et al., 2012). These responses were mediated by intracellular S1P independently of its 
cell surface G-protein-coupled receptors. Also prohibitin 2 PHB2, a highly conserved protein 
that regulates mitochondrial assembly and function, was recently shown to bind S1P in vitro and 
in vivo (Maceyka et al., 2012;Strub et al., 2011;Yester et al., 2011). PHB2 localizes 
predominantly to the inner mitochondrial membrane where it is thought to form a large, 
macromolecular complex with PHB1 that is involved in mitochondrial biogenesis and 
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metabolism (rtal-Sanz & Tavernarakis, 2009;Takasugi et al., 2011) By targeting monomeric 
PHB2 (but not closely related PHB1), S1P is implicated in the regulation of proper assembly and 
function of cytochrome-c oxidase of the mitochondrial respiratory chain in cardiac myocytes 
(Strub et al., 2011). Moreover, PHB is reported to reduce mitochondrial free radical production 
and oxidative stress in brain injury models, perhaps by stabilizing the function of complex I 
(Zhou et al., 2012). Binding of S1P to PHB2 and its action on mitochondrial function represent a 
potential novel link between intracellular S1P binding and ICl,swell, an ion channel activated by 
ROS.  
Several lines of evidence support the possibility that ICl,swell is activated by intracellular 
targets rather than extracellular-facing G protein-coupled S1PR. Intracellular application of both 
S1P and FTY720 elicited larger amplitude currents with a faster time course of activation and 
greater potency than extracellular application. In the case of FTY720, the difference in potency 
was more than 100-fold. These findings are consistent with the notion that S1P and FTY720 
delivered directly to the cytosol via the patch pipette reach their presumed intracellular site of 
action more rapidly and at higher concentration than when the same agents are delivered via 
suprafusion by bath solution. Inclusion in the patch pipette avoids the need for outside-in 
transport via ABC transporters and, perhaps, phosphorylation of FTY720 to FTY720-P by 
SphK2. As a result, the cytoplasmic concentration of ligand is likely to increase more rapidly 
with intra- than extracellular exposure, and if the access of ligand to its intracellular target is rate 
limiting, faster current activation is expected, as was observed.   
The idea that S1P and FTY720 act on intracellular binding sites also may explain the 
inconsistent responses of nominally specific S1PR inhibitors. The ability of these agents to 
inhibit binding of S1P and FTY720 or FTY720-P to intracellular ligands has not been 
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characterized. Nevertheless, our results argue that the putative intracellular binding site is not 
effectively blocked by CAY1044 and VPC23109 or these S1PR antagonists may fail to reach  
intracellular targets. Competitive inhibitors of agonist binding to S1PR presumably possess 
structural features that mimic those of S1P. This raises the possibility that S1PR antagonists 
might compete for binding sites on ABC transporters. Thus, for example, CAY10444 might 
block the action of 500 nM extracellular S1P on ICl,swell by preventing its import, but not suppress 
the response to intracellular S1P because CAY10444 fails to recognize or reach the intracellular 
S1P binding site. On the other hand, CAY10444 also failed to prevent activation of ICl,swell by 10 
μM extracellular FTY720, which must be imported and phosphorylated. The requirements for 
uptake of S1P and FTY720 might be different. Alternatively, CAY10444 might be ineffective in 
competing with a high concentration (10 μM) of FTY720 but still block the uptake of a lower 
concentration (500 nM) S1P by the same transport mechanism. Of particular interest, CAY10444 
and VPC29019 both were ineffective in blocking the response to both S1P and FTY720 applied 
via the patch pipette. Taken together, these data suggest that that the S1PR inhibitors failed to 
recognize or failed to gain access to the intracellular ligand that triggers ICl,swell activation.  
An intracellular ligand model also must explain the ability of SEW2871 to elicit ICl,swell. 
This small molecule heterocyclic S1PR1 agonist is uncharged and lipophilic; its octanol:water 
partition coefficient calculated by XLogP3-AA is 6.6 (see Pubchem Compound 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4077460#x27 accessed 30 March 
2013). This suggests SEW2871 will partition into the plasma membrane, but distribution into the 
cytoplasm has not been studied.  
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4.4 ROS mediated activation of ICl,swell.  
In the present studies we found that intracellular application of 500 nM S1P or 100 nM 
FTY720-P elicited ICl,swell that was insensitive to inhibition of NADPH oxidase by the fusion 
peptide inhibitor gp91ds-tat but was fully suppressed by inhibition of mitochondrial electron 
transport by rotenone in the continued presence of S1P or FTY720-P.  These data argue that S1P 
and FTY720-P augment mitochondrial ROS production and thereby activate ICl,swell by signaling 
that is independent of NADPH oxidase. 
In contrast to this conclusion, previous work by our laboratory established that  ROS 
produced by both NADPH oxidase and mitochondria are essential for eliciting  ICl,swell in 
cardiomyocytes in response to multiple stimuli (Ren et al., 2008;Deng & Baumgarten, 
2009;Browe & Baumgarten, 2007;Browe & Baumgarten, 2006;Browe & Baumgarten, 2004). 
Blockade of NADPH oxidase by gp91ds-tat, apocynin or other agents is sufficient to inhibit 
ICl,swell activated by Ang II binding AT1 receptors, ET-1 to ETA receptors, EGF to EGFR, integrin 
stretch, and osmotic swelling. Nevertheless, these stimuli also increase  mitochondrial ROS 
production in series with NADPH oxidase, and rotenone-sensitive mitochondrial ROS 
production is a required upstream effector for current activation (Deng et al., 2010b;Deng et al., 
2009). On the other hand, as found in the present study, interventions that directly affect 
mitochondrial function are capable of eliciting ICl,swell via mitochondrial ROS production 
(blocked by rotenone) that is independent of NADPH oxidase (insensitive to gp91ds-tat and 
apocynin) (Deng et al., 2010b;Deng et al., 2009;Raucci Jr. & Baumgarten, 2010). Among these 
interventions are: antimycin A, which blocks the electron transport chain distal to the complex 
III Qo site; diazoxide, which is thought to act by opening mitochondrial KATP channels; and the 
HIV protease inhibitors ritonavir and lopinavir. In parallel studies with these agents, ROS 
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production was measured in intact HL-1 cardiomyocytes using C-H2DCFDA-AM fluorescence 
and was fully suppressed by rotenone but not gp91ds-tat. Moreover, effects on mitochondrial 
membrane potential (Δψm) were confirmed with JC-1 in some cases.  
 Our findings that S1P and FTY720-P bind to an intracellular ligand, rather than S1PR, 
and thereby elicit ICl,swell via mitochondrial ROS production S1PR raises an important  question 
that we have not addressed experimentally: What is the intracellular binding site responsible for 
augmenting mitochondrial ROS production? One possibility is Phb2. a highly conserved protein 
that regulates mitochondrial assembly and function, was recently shown to bind S1P in vitro and 
in vivo (MacLennan et al., 2001;Strub et al., 2011;Yester et al., 2011). PHB2 has been shown to 
act as a chaperone in the assembly of subunits of mitochondrial respiratory chain complexes 
(Nijtmans et al., 2002). Moreover, PHB is reported to reduce mitochondrial free radical 
production and oxidative stress in brain injury models, perhaps by stabilizing the function of 
complex I (Zhou et al., 2012). Also, PHB1 downregulation in endothelial cells increases 
mitochondrial ROS production and promotes a senescent phenotype (Schleicher et al., 2008). 
Binding of S1P to PHB2 and its action on mitochondrial function represent a potential novel link 
between intracellular S1P binding and ICl,swell, an ion channel activated by ROS. 
It is unclear whether S1P and FTY720-P will augment mitochondrial ROS production 
independent of NADPH oxidase via an intracellular ligand rather than S1PR and thereby 
stimulate ICl,swell in cells from other tissues. S1P was recently found to increase in H2O2 
production in murine NIH3T3 fibroblasts through NADPH oxidase activation (Catarzi et al., 
2011). This response was PI-3K- and PKC dependent, was similar to PDGF-induced NADPH 
oxidase activation, and was mediated via Gi signaling by S1PR1 and S1PR3. The others did not 
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consider whether mitochondrial ROS production was upregulated by these interventions nor 
whether ICl,swell was activated 
4.5. Implications 
ICl,swell is known to regulate cardiac action potential duration (Kawata et al., 
1974;Vandenberg et al., 1997;EHARA & HASEGAWA, 1983) and cell volume regulation 
(Okada & Maeno, 2001;Shimizu et al., 2004;Hoffmann & Dunham, 1995), and the current is 
persistently turned on under isosmotic conditions in models of dilated cardiomyopathy (Clemo et 
al., 1998); (Baumgarten et al., 2005). Moreover, ICl,swell also has been implicated in apoptotic or 
regulatory volume decrease (Rasola et al., 1999;Okada & Maeno, 2001) that precedes apoptotic 
cell death. To the extent that S1P is elevated during cardiac disease, its effect on ICl,swell may 
contribute to the observed responses. Sphingolipid metabolites are known to regulate the 
function of heart by acting as second messengers to activate various signaling pathway (Karliner 
& Brown, 2009). Ceramide  and S1P accumulate in various cardiac diseases (Chatterjee et al., 
2006;Levade et al., 2001). Furthermore, the sphingomyelin/ceramide pathway is activated in 
vivo during ischemia/reperfusion and heart failure (Karliner, 2009a;Means & Brown, 2009), and 
the oxidation of sphingolipids is implicated in atherosclerotic plaque formation (Holland & 
Summers, 2008). Also during hypoxia and pre-conditioning an increased mitochondrial ROS 
production is associated with sphingolipids in experimental models (Lecour et al., 2006). 
Furthermore, a similar increase in mitochondrial ROS is observed in heart failure model (Sawyer 
& Colucci, 2000). In the present study, we demonstrate the evidence that , S1P and FTY720-
induced current is independent of ROS production from NADPH oxidase, and require only ROS 
production from mitochondria. In addition, one needs to consider the consequences of 
mitochondrial ROS production on other ion channels, transporters and signaling pathways. ROS 
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have multiple targets (for review, see (Thannickal & Fanburg, 2000;D'Autreaux & Toledano, 
2007) ), and one or more of these may contribute to the effects of S1P and FTY720-P in the heart 
and other tissues. S1P has long been known to offer cardioprotection during ischemia-
reperfusion injury (Karliner, 2009a;Karliner, 2009b). Multiple factors may contribute. First, 
interventions that stimulate mitochondrial ROS production can be protective in ischemia-
reperfusion models (Pain et al., 2000;Vanden Hoek et al., 1998;Carroll et al., 2001;Halestrap et 
al., 2004). Nevertheless, the effects activation of ICl,swell by S1P, including regulation of cell 
volume and action potential duration, may also contribute. In particular, we would expect 
activation of ICl,swell and the outwardly rectifying current it generates would lessen the occurrence 
of ventricular arrhythmias associated with action potential prolongation. On the other hand, 
abbreviation of action potential duration shortens the minimum length of the conducting pathway 
required to sustain re-entrant tachyarrhythmia's that can lead to fibrillation. The above 
predictions of the effects of S1P and FTY720-P on arrhythmogenesis based on their modulation 
of ICl,swell are likely to be too simplistic, however. As already noted, ROS production by these 
agents has multiple targets and the response of all the targets must be integrated to fully 
appreciate the consequences for cardiac function.  
4.6 Future Directions 
One of the important direction is to elucidate role of Sphingosine kinase (SphK) in 
production of S1P and modulation of ICl,swell SphK are lipid kinase that catalyzes production of 
S1P from sphingosine by ATP dependent phosphorylation. SphK is stimulated by a variety of 
agonist. Two mammalian cardiac isoforms are known SphK1 and SphK2. The two isoforms 
show different temporal, spatial, and tissue distribution. Though they are responsible for 
production of S1P, due to differences in their expression, S1P produced by action of different 
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isoforms might play different roles and may be involved in different signaling pathway. Both the 
isoforms are expressed in heart. In contrast to SphK1, SphK2 is mainly present in intracellular 
compartments, including the nucleus and mitochondria. Nuclear SphK2 regulates gene 
transcription at least in part by producing S1P, which acts as an endogenous inhibitor of histone 
deacetylases (Hait et al., 2009). In mitochondria the action(s) of SphK are required for correct 
assembly of the cytochrome oxidase complex. However, the exact ligand for the mitochondrial 
targeting signal is not known (Strub et al., 2011). Thus it would be important to understand how 
S1P produced by each isoform affect the modulation of ICl,swell. In order to test this hypothesis, 
we could provide an enzyme which stimulates S1P production by the action of kinase on 
sphingosine. SMase acts on sphingomyelin to produce ceramide, which in turn is converted to 
sphingosine. Sphingosine, upon the action of SphK is converted to S1P. Pharmacological 
blockers of SphK could be used to determine the role of SphK and specifically which isoform is 
involved in modulation of ICl,swell. An experiment design would include the use of SMase in 
control bath solutions. Subsequently a SphK inhibitor N,N-dimethylsphingosine (DMS) and 
D,Lthreo- dihydrosphingosine (DHS), which inhibits both SphK1 and SphK2 could be utilized in 
presence of SMase. Failure to see SMase induced activation of current would demonstrate either 
SphK1or SphK2 or both kinases were required in formation of S1P and thereby in regulation of 
ICl,swell. Furthermore to test which isoform is important (2R,3S,4E)-N-methyl-5-(4'-
pentylphenyl)-2-aminopent-4-ene-1,3-diol, designated SK1-I (BML-258), a potent, water-
soluble, isoenzyme-specific inhibitor of SphK1 (Paugh et al., 2008) applied in the presence of 
SMase. Attenuation of current from control would suggest that SphK1 is the required isoform for 
S1P production in cardiac myocytes and thereby modulates ICl,swell. On the other hand failure to 
inhibit SMase induced current precludes the role of SphK1 would suggest SphK2 as the required 
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isoform. Moreover ABC294640 selective inhibitor of SphK 2 (Becker et al., 1992) be utilized in 
the presence of SMase to confirm the role of SphK2. If the SMase induced current is inhibited 
then it would confirm the role of SphK2 in S1P production in heart. Thus the aforementioned 
experiments would help identify the isoform(s) required for S1P production in heart. Similar 
experiments could be done in presence of ceramide and sphingosine instead of SMase. Ceramide 
and Sphingosine are downstream metabolites of SMase, observation of similar behavior with 
their use will support the metabolic pathway in production of S1P as suggested and corroborate 
the role of SphK in modulating ICl,swell. 
Genetic approach also would be promising in determining the role of SphK and 
identifying the specific isoform involved in modulation of ICl,swell. Knockout mice for SphK 
(SphK1-/-), SphK2 (SphK2-/-) can be used to characterize the role of SphK in regulating ICl,swell. If 
both the isoforms modulate ICl,swell, then the aim would be to identify, if there are difference in 
the regulation of ICl,swell by a specific isoform. To do these experiments isolated cardiac myocytes 
from knockout mice and wild type mice of the same strain would be used. Whole cell patch 
clamp will be used to record the current. SMase will be applied to the cells and the current 
recorded under isosmotic solutions. Failure to see SMase induced current in cells from SphK1 
knockout mice as compared to wild type mice would suggest SphK1 to be a required isoform for 
formation of S1P and thereby activation of ICl,swell. On the other hand failure to observe SMase 
induced current in SphK2 knockout mice as compared with wild type mice would implicate 
SphK2 as the isoform necessary for generation of S1P and modulation of current. As a positive 
control exogenous S1P and intracellular S1P to be utilized in both the knockout mice as well as 
wild type mice. The activation of current by exogenous S1P in all three types of mice would 
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implicate that indeed lack of particular iso-forms of SphK in the K/O mice fails to generate S1P 
upon SMase treatment and hence unable to activate the current. 
 In the present study, we observed that, some intracellular target for S1P is responsible for 
activating the current rather than the GPCS1PR. Hence the next daunting question is to identify 
the intracellular binding site for S1P. 
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